

A review of totally implantable wireless ultrasonic Doppler blood flowmeters: towards accurate miniaturized chronic monitors

Michael A. Rothfuss^a, Jignesh V. Unadkat^b, Michael L. Gimbel^b, Marlin H. Mickle^a, Ervin Sejdić^{a,*}

^a*Department of Electrical and Computer Engineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA, USA.*

^b*Department of Plastic Surgery, University of Pittsburgh, Pittsburgh, PA, USA.*

Abstract

Totally implantable wireless ultrasonic blood flow meters provide direct-access chronic vessel monitoring in hard-to-reach places without using wired bedside monitors or imaging equipment. While the accuracy of wireless implantable Doppler devices satisfies most applications, device size and implant lifetime remain vastly underdeveloped. This paper reviews past and current approaches to miniaturization and implant lifetime extension for wireless implantable Doppler devices, and it proposes approaches to reduce device size and maximize implant lifetime for the next generation of devices. Additionally, this paper reviews current and past approaches to accurate blood flow measurements. This review points towards relying on increased levels of monolithic customization and integration to reduce size. Meanwhile, recommendations to maximize implant lifetime should pursue alternative sources of power, such as transcutaneous wireless power, which stand to extend

*Corresponding Author: Ervin Sejdić, 3700 O'Hara St. Benedum Hall Room 1238 Pittsburgh, PA 15261; E-mail: esejdic@pitt.edu, Phone: 412-624-8003

lifetime indefinitely. Coupling together the results will pave the way for ultra-miniaturized totally implantable wireless blood flow monitors for truly chronic implantation.

Keywords: Batteryless, blood flow monitor, flowmeter, free flap, wireless power, transcutaneous wireless power

1 **Introduction**

2 Microvascular free flap (MFF) surgeries are a class of procedures used
3 in reconstructive surgeries to correct anatomic defects requiring persistent
4 monitoring to ensure surgical success (Hong et al., 2014; Zhou et al., 2014;
5 Kang et al., 2013). MFF surgeries involve the transfer of a tissue block
6 (i.e., flap) from one part of the body (e.g., thigh, buttocks) to another (e.g.,
7 breast, mandible). The arteries, veins, and other connective tissues of the
8 donor tissue are connected to those at the transfer site. The microvascular
9 connections, called anastomoses, establish blood flow to the transferred tissue
10 block (O'Brien et al., 1974; Goodstein and Buncke Jr, 1979). Anastomotic
11 failures (i.e., due to clotting, leaks, etc.) hinder blood flow to the transferred
12 tissue. Unless these failures are caught, the tissue will certainly die (Chen
13 et al., 2007; Wu et al., 2013). MFF monitoring by trained technicians is
14 a necessity to reduce the death of tissue and subsequent risky surgical re-
15 exploration. Of the many MFF monitoring technologies available, few can
16 provide an accurate, easy-to-use, and cost effective combination.

17 All MFF monitoring techniques need to be accurate, and false-positives
18 and false-negatives lead to costly and risky surgical re-exploration. Ease-of-
19 use can be a limiting factor in a monitoring technology's adoption, particu-
20 larly when the technology requires skilled technicians and prevents patient
21 mobility. Early and quick detection (i.e., through monitoring) of the nearly
22 10% to 20% of compromised vessels in free flaps has helped to increase flap
23 salvage rates (Yu et al., 2009; Liu et al., 2012), which has lead to the con-
24 tinued development and exploration of numerous monitoring technologies to
25 minimize lost flaps.

26 Techniques to monitor MFFs are abundant, but many have fallen to dis-
27 use in favor of cheaper and more practical and easier to use alternatives that
28 can service the gamut of applications. Buried flaps, vascularized bone grafts,
29 pigmented skin flaps, skin grafted muscle flaps, and flaps with small skin pad-
30 dles are all challenges that a monitor must face with evaluation. Several mon-
31 itors, such as the fluorescein monitor, thermocouple, photoplethysmography,
32 the transcutaneous laser Doppler, and the transcutaneous P_{O_2} monitor have
33 significant drawbacks which have lead to their disuse (Swartz et al., 1988).
34 Non-invasive near-infrared spectroscopy (NIRS) showed promise with its low
35 false-positive and low false-negative rates. However NIRS monitoring suffers
36 from several drawbacks, which include: a slow response time, an inability to
37 monitor buried flaps, a sensitivity to interfering light sources, and finally, it
38 is cumbersome (Lohman et al., 2013). Even newer monitoring methods such
39 as positron emission tomography (Schrey et al., 2008) and microendoscopy
40 (Upile et al., 2006), are considered cumbersome and impractical. The Cook-
41 Swartz implantable Doppler device, however, offers significant advantages
42 over its competitors. This device allows for direct-contact monitoring of a
43 vessel, which increases the reliability of patency monitoring, particularly for
44 buried free flaps (Disa et al., 1999).

45 Even though the wired implantable Doppler is considered the gold stan-
46 dard in MFF monitoring (Guillemaud et al., 2008; Pryor et al., 2006; Oliver
47 et al., 2005; Rozen et al., 2011), it is not without its shortcomings (Cho
48 et al., 2002; Rosenberg et al., 2006; Paydar et al., 2010), which can be mit-
49 igated through the employment of another Doppler technology, the wireless
50 implantable Doppler (WID) (Rothfuss et al., 2016; Gimbel et al., 2014; Un-

51 adkat et al., 2014). This paper will focus on *totally* implantable WID de-
52 vices using piezoelectric transducers. The review excludes multi-channel and
53 multi-sensor devices (e.g., (Axelsson et al., 2007; Gräns et al., 2009; Kong
54 et al., 2005)), due to their additional size and power consumption, preclud-
55 ing comparisons with other WIDs. The paper will review the major open
56 problems towards developing WIDs for MFF and chronic implantation appli-
57 cations. Published solutions to these problems and the emerging and future
58 directions to solve these problems will follow.

59 **Clinical Blood Flow Monitoring: A Background**

60 *Elements of an Ideal Monitor*

61 The ideal microvascular blood flow monitor is easily deployable and easily
62 interpretable by inexperienced operators, provides continuous and reliable
63 monitoring, tolerated by the patient, and applicable to any site, (Smit et al.,
64 2010). To date, according to Smit et al., the most promising monitors for
65 free flap monitoring are the Cook-Swartz wired implantable Doppler, near-
66 infrared spectroscopy, and Laser Doppler flowmetry. While NIRS and Laser
67 Doppler flowmetry are non-invasive and reliable, they are not applicable to
68 all sites nor easily interpretable like the wired implantable Doppler. However,
69 the wired implantable Doppler suffers from reliability problems. No single
70 technology has achieved these specifications fully, and has left the field open
71 for solutions.

72 In anastomoses cases, deployment simplicity and monitoring reliability
73 have been addressed by using anastomotic flow couplers (Zhang et al., 2012).
74 Major reliability problems with the wired Doppler probe stem from probe

75 placement, for which proper placement requires experience (Yu et al., 2009).
76 The flow coupler conveniently incorporates the probe into the coupler’s rigid
77 ring wall to reduce the placement difficulties. The flow coupler can be rapidly
78 deployed using a hand-held assembly. Recently, monitors have targeted the
79 reliability problems and interpretation difficulties of the wired Doppler gold
80 standard, which stem from its wire tether to a bedside monitor and lead
81 to additional unnecessary surgery (Zhang et al., 2012), by eliminating the
82 problematic wire tether and totally implanting the monitor (Unadkat et al.,
83 2015; Rothfuss et al., 2016). True continuous monitoring requires an unlim-
84 ited power source, which is only currently found in bedside monitoring (i.e.,
85 those using wall outlets). In power constrained applications (i.e., totally im-
86 planted wireless monitors), approximately continuous monitoring has been
87 demonstrated by duty-cycling the implant power-on/sensing time (Vilkomer-
88 son et al., 2008; Cannata et al., 2012; Rothfuss et al., 2016), often achieving
89 years of approximately continuous measurement.

90 Invasive technologies, such as the implantable wired Doppler, are only
91 tolerable in the short-term, due to limiting patient mobility. To-date, all
92 totally implantable blood flow monitors remain overly large and intolerable
93 to patients. The root of the non-ideal implants sizes is shared among: lack
94 of advanced monolithic integration (e.g., (Gill and Meindl, 1975; Di Pietro
95 and Meindl, 1978), power requirements (e.g., battery size (Yonezawa et al.,
96 1992; Vilkomerson et al., 2008; Rothfuss et al., 2016)), and implant antenna
97 size (e.g., telemetry (Vilkomerson et al., 2008) and/or wireless power transfer
98 (Tang et al., 2014)).

100 The financial aspects of free flap monitoring, and cost associated with
101 surgical reexploration represent a barrier towards a monitoring technology's
102 adoption. When free flap failure occurs, the financial costs are high. Fischer
103 et al.'s cost analysis for breast flaps, across 1303 flaps between 2005–2011,
104 showed major surgical complications increased the length of stay to 6.14 days
105 on average with a total average cost of \$28,261, compared to no complica-
106 tions, which incurred 4.20 days on average and an average cost of \$19,106. A
107 cost penalty of \$9,155 and an increased stay of 1.94 days. For head and neck
108 flaps, Gupta's 2010 analysis (in \$CAD) showed failed flaps cost \$1413.73/day
109 for an average stay length of 34.5 days; compared to \$1327.71/day for an
110 18.8 day stay in successful free flap surgeries (Gupta, 2012), a difference of
111 \$23,812.74 more for failures. Dollar amounts in Gupta's analysis were con-
112 verted from Canadian Dollars to U.S. Dollars from the 2010 Canadian-to-U.S.
113 exchange rate of 1.072 as published by the Internal Revenue Service (IRS)
114 (Service, 2016).

115 Another financial aspect of the monitoring period is the cost of the moni-
116 toring device, which vary by many factors, including, accuracy, applicability,
117 ease-of-use, invasiveness, amongst others. Here, we discuss the results of Smit
118 et al.'s review of popular monitoring modalities (Smit et al., 2010). Of the
119 available monitors, the best are the implantable Doppler, the near-infrared
120 spectroscopy, and the laser Doppler flow meter. The implantable Doppler
121 is the cheapest (i.e., \$3100 monitor + \$412 disposable probes), followed by
122 laser Doppler flowmetry (i.e., \$5460 + \$1050 per 10 probes), and then NIRS
123 (i.e., \$16.5k+ \$150 sensors). Other valuable monitors include the familiar

124 color duplex ultrasound machines and microdialysis. However, their cost
125 is significant compared with the three best monitoring choices (i.e., color
126 duplex: \$30k–\$225k; microdialysis: \$52k analyzer + \$570 consumables).
127 While NIRS and Laser Doppler flowmetry are both noninvasive and have
128 100% positive and negative predictive values, their penetration depth is lim-
129 ited and cannot be used for deeply buried flaps (i.e., 20 mm max for NIRS
130 and 8mm max for Laser Doppler). Despite having a lower positive predictive
131 value than NIRS and Laser Doppler flowmetry, the implantable Doppler flow
132 meter can monitor all flap types, including buried flaps, and can be inter-
133 preted by minimally trained or unexperienced personnel, and is considered
134 a simpler technique to use compared to NIRS and Laser Doppler flowmetry.
135 The implantable wireless blood flow monitors stand to improve the adoption
136 of the Doppler monitoring technique by eliminating the root of the wired
137 implantable Doppler’s imperfect positive predictive value – the transcuta-
138 neous wire to the bedside monitor. Cost estimates of the wireless implantable
139 Doppler have yet to be reported in literature.

140 *Clinical and Research Need Summary*

141 While no single monitor is fits the ideal mould, the closest candidates
142 reported in literature are the wired implantable Doppler, near-infrared spec-
143 troscopy, and Laser Doppler flowmetry. Compared these methods, the im-
144 plantable Doppler is the only invasive modality, with the exception that
145 microdialysis is minimally invasive. Table b summarizes the blood flow mon-
146 itoring modalities along with their clinical advantages and disadvantages.

147 The wired implantable Doppler stands out from others as it provides
148 immediate feedback, is easily interpreted by inexperienced personnel, and can

149 be used with any type of flap, including buried flaps. The wired implantable
150 Doppler implantation process requires direct vascular access, which is the
151 root of the technology's success across all flaps; the transcutaneous wire
152 connects the bedside monitor to the sensor affixed to the vessel. After the
153 post-monitoring period, the wire is tugged and breaks free from the sensor
154 and cuff at the vessel site, which remain in the patient permanently. This
155 wire is the source of the implantable Doppler's shortcomings and amounts
156 to reduced reliability, potential for injury, and unnecessary surgeries. The
157 major problems associated with the transcutaneous wire are described by Yu
158 et al. (Yu et al., 2009), Zhang et al. (Zhang et al., 2012), and Kempton et
159 al. (Kempton et al., 2015) and are summarized below:

- 160 • Limited patient mobility which increases the risk of vessel kinking and
161 damage.
- 162 • Easily dislodged internally, resulting in high false-positives and expen-
163 sive and unnecessary surgical re-exploration.
- 164 • Tenuous and cumbersome to have in the operative field after place-
165 ment, due to the potential for inadvertent snagging and dislodgement
166 or injury.
- 167 • Potential for injury to vessels upon removal at the end of the monitoring
168 period.

169 Until recently, the body of literature had not investigated the wireless
170 implantable Dopplers as a competitor to the wired device. Even if future

171 studies confirm the efficacy of the wireless Doppler, the focus of wireless im-
172 plantable Doppler literature has been more on accuracy and implant lifetime
173 rather than the more practical aspects of an implantable monitor, namely
174 its size. The wireless implantable Doppler technology, likewise to the wired
175 implantable Doppler, is intended to remain inside the patient both during
176 and after the free flap monitoring period. Its size is paramount, which di-
177 rectly affects patient tolerability. Literature frequently focuses on wireless
178 implantable Dopplers as chronic monitors. Besides implant size, the power
179 source is predominantly batteries, which are bulky and have limited lifetimes,
180 even if rechargeable. Two worthwhile candidates for providing sufficient and
181 unlimited power to implants in a small size are transcutaneous wireless power
182 and ultrasonic wireless power. To date, literature has not focused on solu-
183 tions to extending implant lifetime using these inexhaustible sources of power,
184 which stand to not only extend the implant lifetime indefinitely but also re-
185 duce implant size, making a more ideal monitor.

186 Wireless restenosis monitoring after stent placement has been an active
187 area of research since 2003, and represents a chronic monitoring application
188 for wireless blood flow monitors. Restenosis is the intraluminal re-narrowing
189 of a revascularized vessel to treat atherosclerosis (i.e., the accumulation of
190 plaque in arterial walls). As an example application, when atherosclerosis
191 occurs in the lower-limb arteries, it is called Peripheral Artery Disease (PAD).
192 PAD is asymptomatic in 20–50% of those with the disease (McDermott
193 et al., 2008), and nearly 50% of cases experience complications within the
194 first year after revascularization. Three years after stent deployment, about
195 63–66% of vessels remain patent (Muradin et al., 2001). Currently, patients

196 visit hospitals every 3 to 6 months to detect restenosis (Radermacher et al.,
197 2001); a wireless restenosis monitor stands to eliminate the need for hospital
198 visits, saving hospitals money and improving patient compliance.

199 In wireless restenosis monitoring, the stent is used as an antenna (Keikhos-
200 ravy et al., 2012, 2014). Current methods of wireless restenosis monitoring
201 either use changes in tissue properties that de-tune the antenna (Occhiuzzi
202 et al., 2011, 2012) (i.e., the degree of detuning is sensed) or a blood pressure
203 sensor (Takahata et al., 2003, 2006; DeHennis and Wise, 2006; Chow et al.,
204 2010). However, no wireless restenosis monitor has been reported to monitor
205 blood flow using the Doppler technique. Despite this gap in literature, dur-
206 ing hospital visits, duplex Doppler ultrasound imaging of the diseased vessel
207 is performed, leading to the conclusion that a Doppler blood flow monitor
208 incorporated into the stent antenna would provide meaningful and familiar
209 modality. The degree of renarrowing is clearly evident as increased turbulent
210 flow (Nelson and Pretor, 1988; Arger and Iyoob, 2004), showing a signifi-
211 cantly broader Doppler spectrum as renarrowing worsens and as much as
212 a 100% peak velocity increase, according to Guo et al. (Guo et al., 1994).
213 Development of an implantable wireless chronic blood flow monitor would al-
214 low for at-home treatment and reduced hospital costs for the nearly 5 million
215 American adults in the U.S. with PAD (Selvin and Erlinger, 2004).

216 **Mechanisms of Doppler Ultrasound and Accuracy**

217 In 1961, Franklin et al. showed that blood flow could be measured by
218 exploiting the Doppler effect with ultrasonic backscattering (Franklin et al.,
219 1961). This was the first report of blood flow measurement using the Doppler

220 effect. This device had direct access to the vessel, and the accuracy was re-
221 ported as 5% of the full scale 100 cm/s. The design was simple and inexpen-
222 sive, and its frequency meter output was linearly related to the instantaneous
223 flow velocity. Therefore, the mean Doppler shift frequency is proportional to
224 the instantaneous blood flow velocity.

225 There are two major Doppler ultrasound configurations for blood flow
226 measurements. The first is the continuous wave (CW) Doppler configura-
227 tion, and the second is the pulsed wave (PW) Doppler configuration (Shung,
228 2005). Both configurations have varying degrees of accuracy depending on
229 the application environment (i.e., flow characteristics, inner lumen diameter,
230 inner lumen shape) and measurement assumptions. A full treatment of error
231 sources and measurement assumptions involved in Doppler ultrasound blood
232 flow determination are described by Gill (Gill, 1985).

233 Figure 2 shows a representative system-level CW Doppler flowmeter block
234 diagram. The high-voltage (HV) driver excites the transmitting transducer,
235 and a high frequency (HF) low-noise amplifier connected to the receiving
236 transducer amplifies the weak echoes from tissue and blood. The echoes are
237 demodulated down to baseband. The sample volume of the CW Doppler is
238 fixed, and therefore, if the sample volume is too large for the application,
239 then the origin of echoes may come from outside the intended target area as
240 illustrated in the figure. Conversely, if the sample volume is too small (i.e.,
241 small relative to the lumen cross sectional area), only a uniform flow profile
242 (i.e., plug flow) can be accurately measured because complex flows types
243 will exhibit dissimilar flow outside of the small sample volume. This notion
244 exposes a limitation of the CW Doppler device: it cannot determine the origin

245 of the echoes in a vessel. The poor spatial resolution means that accurate
246 assessment of volumetric flow is degraded in many blood flow environments.

247 A representative system-level block diagram of the PW Doppler flowme-
248 ter is shown in Figure 1. It uses an HV drive in a pulsed excitation. During
249 lulls between pulses, created by using the transmit/receive (TX/RX) switch
250 for blocking, received echoes across the vessel lumen (i.e., at various depths)
251 are amplified using a time gain compensation amplifier, followed by demod-
252 ulation to baseband. The PW configuration takes flow measurements in
253 small incremental cross-sectional areas. The volumetric flow equals the sum
254 of the product of each cross-sectional areas with the velocity within each
255 cross-sectional area. The PW Doppler is constrained by an upper blood flow
256 velocity limit. That is to say, the highest resolvable Doppler frequency is
257 limited by the PW Doppler’s pulse repetition frequency (PRF).

258 A popular alternative flow metering modality, to the Doppler ultrasound
259 technique used in wireless Doppler blood flow meters, is the transit-time ul-
260 trasonic technique. This technique uses two transducers mounted on opposite
261 sides of the vessel at an angle to the vessel wall. Ultrasonic pulses are trans-
262 mitted from one transducer and received by the other, and then the trans-
263 mitter/receiver roles are switched, leading to an upstream and downstream
264 flow measurement. The time difference of the two transit-times provides an
265 accurate measure of the average fluid velocity that is invariant to many pa-
266 rameters, which significantly affect the ultrasonic Doppler flow meter (Gill,
267 1985), including internal/external vessel diameter and shape, transducer an-
268 gles θ , according to D’Ancona et al. (D’Ancona et al., 1999).

269 At first, the transit-time flow meter would appear superior to the Doppler

270 ultrasound flowmeter; however, a practical problem with the transit-time
271 flow meters is that the resulting time-difference is very small, on the order of
272 10^{-9} s, and electronics to extract the time difference are complex (Webster,
273 1998). If a low enough insonifying frequency is used, the phase difference
274 provides a measure of the time-difference. However, without accurate knowl-
275 edge of the transmitter/receiver phase relationships, and unlike the Doppler
276 ultrasound flow meter, the problem of zero-drift for the baseline zero-flow
277 arises, when parameters such as transducer impedance change, according to
278 Meindl (Meindl, 1972). Phase compensation after implantation increases the
279 complexity, and thus power consumption of the design. Still, also according
280 to Meindl, the transit-time flow meter suffers from flow ambiguity prob-
281 lems, where different velocity profiles can result in the same average velocity,
282 thereby requiring *in situ* user calibration for volume flow (Meindl, 1972).
283 The limitations of the transit-time technique (i.e., complexity, stability, user
284 calibration) have clearly impeded its adoption in the body of published liter-
285 ature for wireless implantable blood flow meters. To the best of the authors'
286 knowledge, there have been no reported wireless blood flow monitors using
287 the transit-time principle.

288 *Wireless Implantable Doppler Devices*

289 *Continuous Wave*

290 Shortly after Franklin demonstrated the use of the Doppler effect to mea-
291 sure blood flow in 1961 (Franklin et al., 1961), Franklin et al. reported a
292 wireless implantable CW Doppler device in 1964 (Franklin, 1964). However,
293 while the blood flow data were reported wirelessly, the device was not totally
294 implantable and the bulk of the equipment was worn in a harness or a helmet.

295 This same wireless implantable CW device developed by Franklin et al. was
296 later benchmarked to report important findings related to accuracy (Franklin
297 et al., 1965): (1) the Doppler frequency shift shows a linear relationship with
298 blood flow, (2) flow can be determined accurately using the frequency shift
299 when the vessel lumen area remains constant, (3) pulsatile flow that modifies
300 the vessel lumen area decreases the accuracy by distorting the linear relation-
301 ship, (4) using the zero crossing counter technique for detecting frequency
302 shift is inaccurate for pulsatile jet-like flows, particularly because of the loss
303 of directional flow information using this technique, and (5) this particular
304 device could not resolve flow below 1 cm/sec because of the 40 Hz lower-limit
305 of the implemented signal processing amplifier bandwidth.

306 Theoretical analysis and optimal designs of CW Doppler flowmeters and
307 CW WID flowmeters began to appear in literature about a decade after
308 Franklin et al.'s original work. Key system parameters and system trade-offs
309 were discussed by Gill et al. (Gill and Meindl, 1973), which include ultra-
310 sonic frequency, burst repetition frequency, transducer diameter, transducer
311 angle, and burst length (i.e., in the case of PW Doppler devices), along with
312 appropriate electronic filters, amplifiers, and radio telemetry. Theoretical
313 analysis of the CW Doppler flow meter reported by Brody et al. (Brody and
314 Meindl, 1974) leveraged the development of an optimal system design for
315 a totally implantable CW WID device, by DiPietro et al. (Di Pietro and
316 Meindl, 1978). Using a zero crossing counter (ZCC), which estimates the
317 mean Doppler frequency shift (Shung, 2005), DiPietro et al. reported good
318 accuracy (i.e., $\pm 20\%$ from theory) for center velocity regardless of lumen
319 diameter or flow profile (i.e., provided the sample volume is small relative

320 to the vessel diameter). However, accurate flow volume estimation still re-
321 mained out of reach due to the uncertainty of flow profile across the lumen.
322 Additionally, the ZCC accuracy is known to decrease if the bandwidth of the
323 Doppler spectrum is wide and if the signal-to-noise ratio is poor (Gill, 1985).

324 In the late 1980s and early 1990s, further reports of wireless implantable
325 Doppler devices appeared in literature. In 1989, Yonezawa et al. reported
326 a nondirectional miniaturized CW Doppler device. (Yonezawa et al., 1989).
327 This device utilized a ZCC to determine blood flow (i.e., relating the mean
328 Doppler shift frequency to flow velocity via the Doppler equation). Though
329 the device was intended for a backpack, suggestions for reducing the size for
330 total implantation were given. Later on in 1992, Yonezawa et al. developed
331 a directional wireless CW device (Yonezawa et al., 1992). Although this
332 device was also not entirely implantable (i.e., the electronics connected to the
333 transducers via transcutaneous leads), its design hinged off of his previous
334 work, which could be implanted with Yonezawa's suggestions. This work in
335 1992 used a method of sensing directional information which differed from
336 its predecessors. This method employed two phase-shifted versions of the
337 totally implantable nondirectional CW flowmeters previously developed by
338 Yonezawa to obtain one low-frequency directional reference signal and one
339 standard Doppler audio signal. Flow was tested *in vitro* over 20 cm/s – 150
340 cm/s flow rates, and the flowmeter output linearity was within $\pm 1\%$ to the
341 actual value.

342 In the new millennium, the CW WID devices turned towards the chronic
343 monitoring of vascular grafts. Within three years, with monitoring and
344 subsequent correction, 20% of vascular grafts are no longer patent; with-

345 out monitoring, 45% are not patent. Vilkomerson et al. developed a di-
346 rectional CW WID to chronically monitor these vascular grafts, with an
347 average blood flow velocity accuracy error less than 5% (Vilkomerson and
348 Chilipka, 2004; Vilkomerson et al., 2008). The accuracy was achieved using
349 ultrasonic double-beam diffraction grating transducers (DGT) (See Section:
350 “Diffraction Grating Transducers”), which enabled angle independent blood
351 flow measurements. Transducer angle was previously reported as a critical
352 system parameter by Gill et al. (Gill and Meindl, 1973), which makes the
353 double-beam DGT a significant advantage over conventional CW and PW
354 transducer configurations. Later work by Vilkomerson et al. achieved aver-
355 age blood flow velocity accuracy errors less than 6%, and a peak blood flow
356 velocity measurement deviating only 1.7% from measurements performed
357 with a duplex ultrasound system (Cannata et al., 2012). Compared to the
358 earlier work, which used a double-beam DGT embedded in a graft wall and
359 operating at an ultrasonic frequency of 20 MHz, this work featured a flexible
360 DGT operating at 40 MHz, which could be wrapped around a vessel for mon-
361 itoring. Yet another DGT-enabled WID was developed and demonstrated by
362 Tang et al. (Tang et al., 2014); however, unlike previous WIDs developed
363 for chronic implantation since the turn of the century, this WID contained a
364 small rechargeable battery, which is charged by transcutaneous wireless in-
365 ductive powering. This device operated with a 30 MHz ultrasonic frequency.
366 Power was delivered to the implant in order to charge a lithium polymer
367 battery for 20 seconds, which provided 5 seconds of blood flow monitoring
368 time. Reports of device accuracy were only available for one measurement
369 (i.e., the peak Doppler shift frequency was equated to a flow rate); compared

370 to a volumetric flow measurement of 24 cm/s, Tang et al. reported 22.6 cm/s
371 flow rate with their device.

372 Also since the turn of the century, research into occlusive/patency WID
373 monitors for MFFs were demonstrated by Rothfuss et. al (Rothfuss et al.,
374 2016) and Unadkat et. al. (Unadkat et al., 2014, 2015) and Gimbel et al.
375 (Gimbel et al., 2014). The authors' device focused on the detection of binary
376 flow states (i.e., flow or no flow). This means that the WID establishes the
377 no flow (i.e., indicative of an occlusion) baseline in order to compare it with
378 subsequent flow measurements. The device was calibrated *in vitro* reporting
379 an accuracy of $< \pm 5\%$ above 8.00 mL/min and between -0.8% and 1.2% at
380 the largest calibrated range. Venous occlusions were reproducibly detected
381 in bilateral femoral veins in pigs across 32 trials.

382 *Pulsed Wave*

383 As described by Allen et al. (Allen et al., 1977), the first mention of
384 a PW Doppler blood flowmeter was in 1969 (Peronneau and Leger, 1969;
385 Wells, 1969; Baker, 1970). Gill et al. (Gill et al., 1971) and McLeod et al.
386 (McLeod and Anliker, 1971) (as cited by Allen (Allen et al., 1977)) were also
387 responsible for early developments with PW Doppler devices, but it was Gill's
388 work that directly lead to a number of future developments incorporating his
389 work.

390 The PW WID was first described by Gill (Gill and Meindl, 1973), and
391 the optimal system parameters for the PW WID design were discussed. The
392 preliminary *in vitro* experiments with Gill's PW WID showed a $\pm 15\%$ blood
393 flow volume estimation (Gill and Meindl, 1975). Soon after the development
394 of Gill's PW WID, a nondirectional PW WID was demonstrated by Henry

395 et al. (Allen et al., 1977), which could sample eight velocity points across
396 its cuff – 11 mm inner diameter. Over 77 trials, the accuracy was $+2.0$
397 $\pm 8.7\%$, showing improvement over the first PW WID demonstrated by Gill
398 in 1975. It was suggested that the accuracy overestimation was due to slight
399 variations in the transducer angle. Allen et al. later reported circuits for
400 a bidirectional PW WID to improve upon the accuracy of the previously
401 developed nondirectional PW WIDs (Allen et al., 1978). However, no ac-
402 curacy measurements were reported for this device. Additionally, a unique
403 variation of a PW WID, compared to other reported PW WID devices, was
404 demonstrated shortly after Gill’s first report on PW WIDs by Hartley et
405 al. (Hartley and Cole, 1974). This unique variation accomplished chronic
406 implantation by transcutaneous wireless excitation of the probe itself. That
407 is to say, the leads of the probe were formed into a coil near the surface of
408 the skin prior to surgical closure of the animal, and an external coil magnet-
409 ically couples to the implanted probe. In this study, probes were calibrated
410 for each vessel to remove the typical uncertainties in lumen center velocity,
411 lumen diameter, and crystal alignment.

412 In recent years, an inductive/magnetic powering or power delivery pur-
413 posed for or to a WID has been developed. Tang et al. reported an ultrasonic
414 pulser that could be magnetically powered (Tang et al., 2011); although, the
415 device was not tested in animals and no blood flow accuracy data were re-
416 ported, their device is described as a potential candidate for future studies
417 that measure blood flow. The device may show promise as a chronically
418 implantable device if its accuracy is acceptable.

419 *Doppler Ultrasound Accuracy Summary*

420 Since the development of implantable Doppler blood flow monitors in the
421 early and late 1960s, there has been significant attention towards improv-
422 ing their accuracy. By understanding the sources of error, new techniques
423 were developed and incorporated into the Doppler devices, such as ZCCs,
424 directional flow measurements, range-gated pulse-wave measurements, uni-
425 form insonification, etc. For example, directional flow monitors improve upon
426 nondirectional monitors because for flow situations exhibiting flow reversal,
427 such as in the splenic vein or variations with the cardiac cycle in the aorta.
428 Ignoring the direction of flow will give an inaccurate understanding of the flow
429 characteristics. To expound on another example, the range-gated pulse-wave
430 WID devices solve the problem of unknown vessel dimensions and lumen di-
431 ameter, which vary across measurement site and subject. The range-gated
432 pulse-wave WID can selectively resolve flow at specific ranges away from the
433 transducer face, thereby obtaining high spatial resolution for accurate flow
434 profile assessment and accounting for variations in vascular dimensions.

435 Table b summarizes major WID devices reported in literature along with
436 their reported accuracy. From the table, it is noted that the PW WID
437 devices demonstrate greater accuracy for the blood flow rate in a vessel,
438 compared with the CW WID devices. This is explained by the fact that
439 PW WID devices measure flow at various sample volumes across the entire
440 vessel lumen, which provides information about the flow profile of blood flow
441 in a vessel. Additionally, the directional flowmeters generally show better
442 accuracy over the nondirectional flowmeters.

443 **Miniaturization**

444 Device size is a critical metric WID devices throughout literature. The
445 size of a device imposes a foreign body response by the host (Morais et al.,
446 2010). A large implanted device can cause patient discomfort and may be
447 impractical.

448 *Commercial Off-the-shelf*

449 Commercial off-the-shelf (COTS) parts are a practical and convenient
450 way to satisfy quick development schedules, develop proof-of-concepts, and
451 perform exploratory research at a low cost. Many studies reported in liter-
452 ature with WIDs, both CW and PW, are either mostly or completely de-
453 signed with COTS parts (Vilkomerson et al., 2008; Yonezawa et al., 1989;
454 Allen et al., 1978; Tang et al., 2014; Cannata et al., 2012). COTS parts
455 include monolithic integrated circuits (IC), connectors, jacks, discrete elec-
456 trical components (i.e., resistors, capacitors, inductors), etc. They are routed
457 and connected on a planar substrate, often multi-layer, called a printed cir-
458 cuit board (PCB) to facilitate interconnections between the individual COTS
459 parts.

460 WID size reduction with COTS parts can be accomplished in several ways:
461 two-sided COTS mounting (e.g.,(Vilkomerson et al., 2008)), multilayer PCBs
462 (e.g., (Rothfuss et al., 2016)), and highly integrated ICs (e.g., (Vilkomerson
463 et al., 2008; Gill and Meindl, 1975; Rothfuss et al., 2016)). Two-sided PCBs
464 allow COTS parts to be mounted on both sides of the PCB, thereby shorten-
465 ing interconnections. Multilayer PCBs can be used with two-sided mounting
466 to increase the interconnection density by routing signals, power, and ground

467 within the planar PCB itself. Highly integrated ICs offer the greatest amount
468 of function in the highest density footprint; radios, microcontrollers, voltage
469 regulators, temperature sensors, etc. can all be integrated into a single sili-
470 con die (e.g., CC1110 by Texas Instruments, TX, used by Rothfuss et al. in
471 MFF monitoring (Rothfuss et al., 2016)). Nearly all present-day COTS com-
472 ponents used in products are available in a surface mount technology (SMT)
473 package, which allows components to be directly mounted on the PCB sur-
474 face, rather using legacy through-hole mounting. SMT devices are typically
475 small and allow for high PCB component densities. These techniques are
476 typically combined to reduce the device size. The work done by Rothfuss
477 et al., Unadkat et al., and Gimbel et al. shows a CW WID device that
478 achieved the smallest reported electronics volume by combining multilayer
479 PCBs, highly integrated ICs, and SMT COTS parts (Unadkat et al., 2014;
480 Gimbel et al., 2014; Unadkat et al., 2015; Rothfuss et al., 2016).

481 *Advancements in monolithics*

482 Despite the advantages of COTS parts, they ill-suited for chronic implan-
483 tation, due to their large footprint, compared with ICs. Highly integrated
484 circuits reduce a design’s real-estate. By incorporating a large number of
485 transistors and components on silicon, enormous space savings can be ob-
486 tained compared with COTS and PCB implementations.

487 While completely integrating a WID’s functions on a single silicon die
488 may seem like the overwhelmingly obvious solution towards miniaturization,
489 manufacturing costs can be a significant development barrier. Newer fabrica-
490 tion generations offer the greatest area- and power-savings and performance,
491 but their cost can be prohibitively high. For example, a modern 65 nm mask

492 set (i.e., available since 2006) can cost nearly \$3 Million, while a mask set for
493 an older process, the 0.35 μm node (i.e., available in 1995), can cost greater
494 than an order of magnitude less (Wilson and Ismail, 2006).

495 CW and PW Doppler designs are highly dependent on analog circuits.
496 Digital circuits are better suited for complimentary metal-oxide-semiconductor
497 (CMOS) processes and analog circuits are better suited for a bipolar process.
498 However, according to Baker (Baker, 2011) more than 95% of all manufac-
499 tured integrated circuits are fabricated in a CMOS process. Therefore, de-
500 vices with analog circuitry, such as WIDs, will likely be manufactured in a
501 CMOS, rather than bipolar process. The digital circuits benefit greatly with
502 each new process generation; however, analog circuit feature sizes have re-
503 mained relatively unchanged, which obviates the cost-savings per area benefit
504 offered by newer and more expensive process generations. Additionally, the
505 yield of analog circuits is considerably less than digital circuits. When a sil-
506 icon die contains both analog and digital circuits, the yield becomes limited
507 by the yield of the analog circuits on chip (Wilson and Ismail, 2006). There-
508 fore, from a cost savings standpoint, it may be prudent for WID research to
509 pursue legacy process generations, such as the 0.35 μm process.

510 Throughout the entire body of published WID devices and studies, few
511 have investigated monolithic's usefulness in WID devices. In fact, no studies
512 have produced a totally integrated WID; rather, most incorporate several ICs
513 and some discrete components. The earliest mention of a monolithic inte-
514 grated implantable Doppler flowmeter was in 1969 by Meindl et al. (Meindl
515 et al., 1969), and then again in 1972 by DiPietro et al. (DiPietro and Meindl,
516 1972), followed by continued development on the micropower integrated cir-

517 cuits by Frescura and DiPietro in 1976 and 1977 (Frescura and Meindl, 1976;
518 DiPietro and Meindl, 1977). Even without a total monolithic implementa-
519 tion, the space-savings afforded by using several ICs improved on prior WID
520 implant size by a factor of 5 to 10 while consuming an order of magnitude less
521 power (Di Pietro and Meindl, 1978). DiPietro’s CW WID, reported in 1978
522 measured less than 36 cm^3 . Another WID, a PW configuration, reported in
523 1975 by Gill (Gill and Meindl, 1975), measured 60 cm^3 , and its integrated
524 circuit design was detailed by Gill et al. in (Gill, 1975). Later on, a smaller
525 and bidirectional PW WID was developed by Allen et al. which measured
526 $3.8 \times 2.8 \times 0.8\text{ cm}$ (Allen et al., 1978). Present day WIDs continue to use
527 the same multiple-IC and discrete component implementations, albeit with
528 increased levels of integration with more functions to be integrated into the
529 same IC package (Vilkomerson and Chilipka, 2004; Vilkomerson, 2008; Tang
530 et al., 2014; Rothfuss et al., 2016).

531 *External demodulation*

532 Efforts to reduce implant volume have resulted in another minimization
533 technique, where extracting Doppler baseband information takes place at a
534 device external to the monitored subject. The high frequency flow signals
535 are telemetered to an external device by modulating the carrier frequency of
536 a wireless link (i.e., typically an inductive link). Despite size reduction being
537 the goal, the inductive links used to implement this technique use large coils,
538 which add bulk. The CW WID developed by Cathignol et al. amplified the
539 transduced blood flow signal followed by telemetering it remotely (Cathignol
540 et al., 1975). The telemetry coil was $4\text{ cm} \times 4\text{ cm}$, but no further details
541 regarding size were reported by the authors. A CW WID device developed

542 by Tang et al. also used this technique (Tang et al., 2014); however, their
543 device used two coils. One larger coil provided power to recharge a battery,
544 and a smaller coil solely for telemetering data to an external device, where
545 the blood flow information was demodulated. The device coils required 2.5
546 cm and the area of the two PCBs occupied 7 cm².

547 Yonezawa et al. also reported devices that performed the demodulation
548 and processing externally (Yonezawa et al., 1989, 1992). The Doppler flow
549 information modulates an FM transmitter radio signal, which is then received
550 externally and then filtered, demodulated, etc. Gill and Meindl (Gill and
551 Meindl, 1975) and Allen et al. (Allen et al., 1978) demonstrated a variation
552 of this technique with their PW WIDs, by demodulating on the implanted
553 device, but performing the sample/hold and filtering externally. Gill and
554 Meindl's device occupied 60 cm³, with 20 % of the volume contributed by
555 the electronics. Allen et al.'s device measurements were described in Section
556 "Advancements in monolithics". Additionally, a unique variation on this size
557 minimization technique was implemented by Hartley and Cole (Hartley and
558 Cole, 1974). Their PW WID device used an implanted 3 cm diameter coil
559 that connected directly to the transducer. Thereby locating all electronics
560 externally.

561 *WID Miniaturization Summary*

562 A summary of the miniaturization techniques used throughout the devel-
563 opments of WIDs, both CW and PW, are shown in Table b. From the table,
564 it is noted that the size of WIDs have stayed the same as those developed in
565 the late 1960s and 1970s. This can be explained by noticing that the studies
566 since the turn of the century have focused on proof-of-concept development

567 of advanced techniques improving accuracy (see Section: “Mechanisms of
568 Doppler Ultrasound and Accuracy”), advancements in transducers (see Sec-
569 tion: “Diffraction Grating Transducers”), wireless power (see Section: “Al-
570 ternative power sources & safety limitations”), etc.

571 It should also be mentioned that the power source plays a crucial role
572 in the size of the implant. For example, in the design of the PW WID by
573 Gill in 1975 (Gill and Meindl, 1975), only 20% of the entire 60 cm^3 implant
574 is occupied by electronics; Gill suggests that implant volume can be greatly
575 reduced by replacing the battery with an inductive power link. However,
576 Gill’s PW WID consumes multiple milliwatts of power, which is likely to
577 exceed specific absorption rate (SAR) limits mandated by the FCC (Rabaey
578 et al., 2011). Therefore, Gill’s implant would need further size and power
579 reductions to permit wireless powering, but even with wireless power-enabled
580 WIDs, the reported wireless techniques for the WIDs (Tang et al., 2014) and
581 similar devices (Tang et al., 2011) is still multiple centimeters in size. It
582 should be mentioned that special attention towards minimization of wireless
583 power links is currently a rich field of research (see Section: “Alternative
584 power sources & safety limitations”).

585 Future WID miniaturization efforts should focus on increased silicon in-
586 tegration (i.e, towards a system on a chip), which will lead to ultra-small
587 devices for chronic implantation. Recent research into ultra-miniaturized
588 implants has also pursued ultra-low power implementations, which can run
589 on scavenged energy or small batteries. Ultra-low power integrated circuit
590 designs have been reported for numerous biological implant devices (e.g., for
591 ECG, EEG, cochlear implants, etc.) (Neihart and Harrison, 2005; Sarpeshkar

592 et al., 2005; Verma et al., 2010; Burke and Gleeson, 2000; Fay et al., 2009)
593 in low-cost technology nodes (e.g., 0.5 μm , 0.8 μm , etc.). However, the WID
594 has been absent in integrated circuit literature since the late 1970s. Since
595 the 1970s, significant research into ultra-low power techniques (Sarpeshkar,
596 2010), and higher speed and smaller size transistors have surfaced, which
597 have not been exploited for WID miniaturization.

598 **Power Sources and Lifetime**

599 The power source is an integral part of WID design and lifetime. Bat-
600 teries are the major go-to source for power, but they are often bulky and
601 their lifetime is limited. Transcutaneous wireless power offers an unlimited
602 implant lifetime, but its appearance in WID literature is scarce. This section
603 discusses power sources and alternative power sources, as well as, suggests
604 future directions for power savings specific to WIDs.

605 *Battery Power*

606 Battery power is the most prevalent WID power source reported in litera-
607 ture. Reported WIDs employ various types of batteries, each with their own
608 limitations and advantages. For example, the WID developed by DiPietro
609 used a 1.35 V mercury cell (Di Pietro and Meindl, 1978). The advantage of
610 the mercury battery is that it can maintain its rated voltage for years. How-
611 ever, due to the toxicity of the mercury contained within these cells, they can
612 no longer be purchased in most countries, and are not suited for future WID
613 designs. Pacemaker batteries can also be found in WIDs and offer an avenue
614 for chronic implantation. Using pacemaker batteries, the implants developed
615 by Vilkomerson (Vilkomerson and Chilipka, 2004) and Cannata (Cannata

616 et al., 2012) can operate up to ten and nine years, respectively. The model
617 reported by Vilkomerson is bulky and largely dominates the WID implant
618 size, making it ill-suited for chronic implantation. Smaller pacemaker batter-
619 ies do not necessarily translate to reduced size for chronic implanation. For
620 example, the smallest available pacemaker, the MicraTMTranscatheter Pacing
621 System, achieved its longevity by improving the implanted electronics power
622 consumption by an order of magnitude (Roe, Online; accessed 2016-09-25).

623 The high energy density and current sourcing capacity of lithium batteries
624 makes them particularly useful for power demanding applications requiring a
625 small footprint, such as cell phones, laptops, and implantable medical devices.
626 Another advantage of some popular lithium battery chemistries is their high
627 terminal voltage over the discharge cycle, such as in the case of lithium-ion
628 polymer batteries (i.e., 3.7 V). WIDs reported by Vilkomerson (Vilkomerson
629 et al., 2008), Tang et al. (Tang et al., 2014), and Rothfuss et al. and
630 Unadkat et al. and Gimbel at al. (Unadkat et al., 2014; Gimbel et al., 2014;
631 Unadkat et al., 2015; Rothfuss et al., 2016) all make use of rechargeable
632 lithium batteries. Lithium cell size and energy density are likely to continue
633 fueling their popularity for future WID development.

634 *Alternative power sources & safety limitations*

635 Alternative sources of power are attractive because they offer an unlim-
636 ited implant operational lifetime. Chronic implant studies requiring years
637 of monitoring, such as in artificial grafts, can benefit greatly from alterna-
638 tive power sources. To date, there are many identified alternate sources
639 of power (Chandrakasan et al., 2008; Denisov and Yeatman, 2010; Rabaey
640 et al., 2011; Olivo et al., 2011), including thermoelectric, light, kinetic motion

641 harvesters (i.e., piezoelectrics, electromagnetic, and electrostatic), near-field
642 wireless power, far-field wireless power, ultrasonic power, etc. However, it is
643 the dominant source of power consumption and the WID environment that
644 dictate which of these alternative power sources are suitable. Two common
645 WID components dominating the power consumption are the wireless ra-
646 dio (i.e., for telemetry) and the ultrasonic transducer driver. Wireless radio
647 power consumption can be duty cycled to consume a low average power (See
648 Section: “Low power standby modes”), but typical instantaneous current
649 draws are in the low milliampere range. As for the transducer drive power,
650 the lowest power consumption reported to date is 500 μW by Vilkomerson
651 and Chilipka (Vilkomerson and Chilipka, 2004). Therefore, of the available
652 alternative power sources, only the highest energy densities (e.g., transcu-
653 taneous wireless near-field powering and ultrasonic powering) are suitable
654 for providing unlimited implant operational lifetime at the requisite power
655 demands in a small implant size.

656 Transcutaneous wireless powering (TWP) is a rich field of research (Rabaey
657 et al., 2011; Zhang et al., 2009; Si et al., 2008; Zargham and Gulak, 2012; Jow
658 and Ghovanloo, 2007; Poon et al., 2007; Kiani et al., 2011), which is beyond
659 the scope of this review. Recently, Several important milestones in TWP
660 have been reported which have garnered significant attention. Motivated by
661 a need to reduce the size of bulky implanted antennas for TWP, Poon et al.
662 discovered that an optimal excitation frequency exists, based on new analysis
663 of electromagnetic interactions with the various tissues in the body (Poon
664 et al., 2010), and mid-field powering, rather than far- or near-field offers the
665 greatest power availability for deep-seated implants without exceeding SAR

666 limits (Cleveland et al., 1997). Historically, TWP antennas were bulky due
667 to the relation that electromagnetic power loss in the body increases with
668 increases in frequency (i.e., $\lambda \propto \frac{1}{f}$) (Akin et al., 1998; Liu et al., 2000; Sauer
669 et al., 2005). The work by Poon et al. (Poon et al., 2010) analyzed the
670 optimality of the TWP frequency from the perspective that an implant will
671 lie beneath a heterogeneous stackup of tissues (i.e., skin, fat, muscle, etc.),
672 depending on the application. It is the difference in electromagnetic prop-
673 erties (i.e., permittivity, conductivity, etc.) of different tissues in a specific
674 stackup (i.e., layer order) that leads to the understanding that the implant
675 location will dictate the optimal frequency. Typically, the optimal frequency
676 for most WPT-enabled implants lies in the 100s of MHz. Another significant
677 advantage of TWP in the near- and mid-fields is that a single antenna can
678 be used to both power the implant and telemeter data. If an implanted an-
679 tenna were to be dedicated to TWP, then a second antenna would be needed
680 for a radio transmitter, which draws considerable power, to telemeter data,
681 adding additional bulk to the implant. The same circuitry used in RFID
682 tags to send data back towards the external antenna/system is used in near-
683 and mid-field powered medical implants, which makes data communication
684 readily integrable with monolithic circuits.

685 To date, only one study has demonstrated TWP for a WID (Tang et
686 al. (Tang et al., 2014)). However, the reported WID also made use of an
687 implanted battery, which was recharged through TWP. Additionally, one
688 study developed a unique method to enable an unlimited lifetime for chronic
689 implantation studies. This study, by Hartley and Cole (Hartley and Cole,
690 1974), coiled the ultrasonic probe’s lead wires to form a coil, which could

691 be electromagnetically coupled to by an external transformer coil integrated
692 with a Doppler blood flowmeter; therefore, no electronics were implanted,
693 only a coil and the ultrasonic probe. The novel minimalist approach to wire-
694 less flow monitoring employed by Hartley and Cole appeared to achieve what
695 others could not: minimizing foreign material and minimizing implant com-
696 plexity. However, for unclear reasons, the body of published literature has
697 progressed with implanted electronic blood flow meters rather than Hartley's
698 implementation. Neither Tang et al. nor Hartley and Cole reported on the
699 safety of their transcutaneous wireless powering implementation (i.e., SAR
700 limits), which may limit adoption of their unique approaches to chronic im-
701 plantation. Future WID studies using TWP cannot neglect tissue heating
702 effects.

703 Over the past decade, research has demonstrated the viability of using de-
704 ployed stents (i.e., for treating atherosclerosis) as the TWP antenna, thereby
705 eliminating the concerns over antenna bulk. Many different solutions to
706 chronically and wirelessly monitor restenosis without a battery. Early ef-
707 forts by Takahata et al. in 2003 (Takahata et al., 2003) and 2006 (Takahata
708 et al., 2006) used a custom micromachined stent that when deployed, formed
709 a coil meant to resonate with the capacitance of a capacitive pressure sensor;
710 changes in intraluminal pressure (\propto flow rate) shows a shift in the resonant
711 frequency. Another pressure sensitive device, developed by DeHennis et al.
712 (DeHennis and Wise, 2006), incorporated an integrated circuit along with
713 its pressure sensor, but used a flexible spiral TWP antenna, rather than a
714 stent, to fit within a vessel. DeHennis et al. recognized that maximizing
715 the implanted antenna area would maximize coupling with the external an-

716 tenna, and suggested that the stent frame would satisfy this purpose. It
717 was not until 2009, by Chow et al. (Chow et al., 2009), that the optimal fre-
718 quency of the deployed stent in its environment was investigated, finding that
719 2.4 GHz performed best for cardiovascular stents in the chest. Chow et al.
720 later demonstrated an intraluminal pressure monitor using the stent for the
721 telemetry link, and secondary 3.7 GHz antenna for TWP (Chow et al., 2010).
722 Between 2011 and 2012, Occhiuzzi et al. demonstrated a restenosis monitor
723 by investigating changes in backscattered power due to dielectric property
724 changes of the different atherosclerotic plaques (Occhiuzzi et al., 2011, 2012).
725 However, it wasn't until 2012 that the first optimal TWP link using only a
726 stent (i.e., no additional antennas for communicating or powering) was inves-
727 tigated by Keikhosravy et al. (Keikhosravy et al., 2012), who also considered
728 the SAR effects of such an implementation in the chest. Keikhosravy et al.
729 demonstrated the TWP stent-only power harvesting and communication sys-
730 tem at 2.4 GHz using a custom designed ultra-low power integrated circuit
731 (Keikhosravy et al., 2014). Keikhosravy's work shows the most promise when
732 considering outfitting the stent antenna with Doppler blood flow transduc-
733 ers for flow monitoring. However, the power consumption for Doppler blood
734 flow monitors remains significantly higher than the capacitive pressure sensor
735 restenosis monitors (e.g., DeHennis et al. – $340\mu\text{W}$). Therefore, applications
736 where a lower operating frequency can be used (i.e., to minimize power lost
737 in tissue), such as for PAD in the lower limbs which uses larger stents than
738 those in the chest, stands to increase the available power for the implant.

739 While TWP is the preferred power transfer scheme at short distances (i.e.,
740 1 cm), it performs poorly for deeply seated implants. At deep implants depths

741 (i.e., 10 cm), ultrasonic power transfer shows greater efficiency (Denisov and
742 Yeatman, 2010). This makes ultrasonic powering a better choice for WIDs
743 used for monitoring applications such as coronary bypass grafts and buried
744 free flaps, which are only accessible by current battery-powered WIDs and
745 the wired implantable Doppler, and lay at distances beyond the reach of
746 other popular blood flow monitoring techniques such as Laser Doppler or
747 NIRS. The European Ultrasponder Project has been a recent effort in power
748 delivery and wireless communication using ultrasound rather than electro-
749 magnetic waves (Mazzilli et al., 2010). The project focuses on milliwatt
750 power delivery at depths of 10–20 cm (Cotté et al., 2012; Mazzilli et al.,
751 2014) via Radziemski and Makin (Radziemski and Makin, 2016). A major
752 advantage of ultrasonic powering and communicating compared with TWP
753 is its invariance to electromagnetic radiation, which eliminates hazardous
754 electromagnetic interference with medical devices such as pacemakers (Van
755 Der Togt et al., 2008).

756 A practical issue with ultrasonic powering for WIDs is large acoustic fields
757 in proximity to the ultrasonic piezoelectric transducers used to sense Doppler
758 blood flow signals. This scenario is tantamount to the same problem in
759 mobile communication systems where nearby strong interfering signals
760 severely impact communication channels (Razavi, 1996). Sufficient frequency
761 selectivity of front-end electronics and the Doppler-sensing transducers would
762 be necessary in order to reject the interference and in order to combine the
763 benefits of ultrasonic powering with Doppler blood flow monitors. A potential
764 solution to using ultrasonic powering with WIDs is to enable the ultrasonic
765 link to charge an energy storage element, such as a battery or supercapacitor.

766 Then, when blood flow data is to be collected, the ultrasonic link is disabled.
767 This method was utilized by Tang et al. to electromagnetically wirelessly
768 power a WID (Tang et al., 2014). A disadvantage to this technique is that
769 continuous monitoring is no longer possible, which abandons the continuous
770 monitoring tenet of the ideal blood flow monitor described by Smit et al.
771 (Smit et al., 2010).

772 Powering an implantable device, or recharging a battery on the device,
773 is not without limit. The transmission of energy through tissue results in
774 unwanted heating. For electromagnetic TWP, the heating is caused by ab-
775 sorption (Bernardi et al., 2000), but for the ultrasonic powering case, the
776 heating is caused by both absorption and cavitation (Dalecki, 2004). Reg-
777 ulatory limits on the maximum permissible rise in temperature effectively
778 limit the amount of power that can be transmitted through tissue to a power
779 harvesting implant. As transmission efficiency decreases (i.e., due to the
780 electromagnetic (Gabriel et al., 1996) and acoustic attenuation properties of
781 tissues (Culjat et al., 2010)), less power is available for the implant, neces-
782 sitating power efficient electronics topologies or bulky storage elements such
783 as batteries. For ultrasonic power delivery, limitations for the continuous
784 powering case are more applicable (i.e., rather than pulsed excitation) for
785 wireless implantable Doppler devices, in particular if the implant foregoes an
786 implantable battery to reduce bulk, and if the device is to be a truly contin-
787 uous monitor (i.e., not “approximately continuous” as discussed in Section
788 b for ideal monitors). However, according to Radziemski and Makin’s 2016
789 review of continuous ultrasonic power delivery to charge a battery, the body
790 of literature regarding its safety is limited (Radziemski and Makin, 2016).

791 Radziemski and Makin demonstrated safe power deliveries of 600 mW and
792 50 mW to implanted batteries at 10–15 mm and 50 mm, respectively, over a
793 total of 10.5 hours during a five-week period. The implanted receiver trans-
794 ducer was circular and 25 mm in diameter and the operational frequency
795 was 1 MHz. For electromagnetic TWP, the SAR limitations are well-known.
796 For 1 gram of tissue, the average power cannot exceed 1.6 W/kg, while the
797 average power in 10 grams of tissue cannot exceed 2 W/kg over 6 minutes
798 (Kiourti et al., 2011). Recent work in the field of TWP, by Poon et al. (Poon
799 et al., 2010), has demonstrated continuous safe power delivery in the milli-
800 watt range for depths of several centimeters using a millimeter-sized receiver
801 at about 1 GHz. Comparing the power delivery and ultrasound, ultrasound
802 power delivery systems typically operate in the low-MHz due to a compro-
803 mise for penetration and tissue heating (Denisov and Yeatman, 2010; Cotté
804 et al., 2012). Whereas, the TWP demonstrated by Poon et al. operated at
805 a carrier frequency three orders of magnitude greater – about 1 GHz. Not
806 only does the smaller wavelength permit significant miniaturization, but a
807 major benefit of a higher carrier frequency is that it can support higher data
808 rates.

809 *Other Approaches to power savings*

810 Throughout WID literature, there have been several alternative approaches
811 towards minimizing power consumption and maximizing implant lifetime
812 that have proved successful.

813 *Ultrasonic Frequency and Blood Backscattering*

814 As reported early on in WID history by Gill and Meindl (Gill and Meindl,
815 1973), ultrasonic operational frequency is a critical system design specifica-
816 tion. The majority of WID devices reported in literature operate in the low
817 MHz range (i.e., <10 MHz). Vilkomerson described the benefits of increas-
818 ing the ultrasonic frequency (Vilkomerson and Chilipka, 2004; Vilkomerson
819 et al., 2008; Cannata et al., 2012), which include greater signal-to-noise ra-
820 tios for a given power drive for the transmitting transducer. Vilkomerson’s
821 early reported WIDs were a CW configuration operating at 20 MHz. Later
822 reports by the same author demonstrated 30 MHz and 40 MHz variations of
823 the same WID.

824 Physical and biological mechanisms in an application environment affect
825 selection of ultrasonic frequency. With direct access to a vessel, the ultrasonic
826 wave travels through and impinges on the vessel wall and the blood within
827 the vessel lumen. An optimal frequency can be established by accounting
828 for the attenuation and scattering properties of the vessel wall and blood,
829 which are functions of frequency. The goal is to minimize attenuation from
830 the vessel wall and maximize backscattered energy from the blood. Hoskins
831 established equations to predict these properties gathered from available liter-
832 ature (Hoskins, 2007). Hoskins’ review shows that 20 MHz is a good trade-off
833 between attenuation and backscatter. Blood backscattering holds a nearly
834 f^4 dependency, which indicates Rayleigh scattering. Noteworthy devices
835 that operate at 20 MHz are the gold-standard Cook-Swartz wire Doppler
836 and several reported WIDs (Vilkomerson and Chilipka, 2004; Vilkomerson
837 et al., 2008; Unadkat et al., 2014; Gimbel et al., 2014; Unadkat et al., 2015;

838 Rothfuss et al., 2016). As an example, using Hoskins' review, for the same
839 transducer drive power, over 22 dB more backscattered power is available
840 for these 20 MHz implementations compared with the 6 MHz CW WID by
841 DiPietro (Di Pietro and Meindl, 1978). Therefore, attention to ultrasonic
842 frequency in WID design is imperative to achieve high signal-to-noise ratio
843 for a given drive power.

844 *Low power standby modes*

845 *Continuous* monitoring with chronically implanted WIDs, employing a
846 battery, will render the device's power source depleted quickly. Duty cycling
847 the battery usage is a convenient way to increase implant lifetime when the
848 application can tolerate intermittent monitoring. In 2008, Vilkomerson et
849 al. developed a CW WID capable of a 35 year implant lifetime with one
850 measurement per day or an eight year lifetime with eight measurements per
851 day (Vilkomerson et al., 2008). A study by Cannata et al. in 2012, using
852 nearly the same device from Vilkomerson et al.'s 2008 study, provides a nine
853 year lifetime with four measurements per day (Cannata et al., 2012). By duty
854 cycling the battery usage, power draw remains in the micro- or nanowatt
855 levels when the device isn't taking a measurement. This is accomplished
856 through the use of electronics capable of powering themselves into a low-
857 power mode (i.e., often called a sleep mode).

858 Low-power modes are a common feature in many electronic devices. Early
859 WID devices were outfitted with an RF switch (Gill et al., 1976; Di Pietro
860 and Meindl, 1978), which allowed the totally implanted WID to be wirelessly
861 activated for when a measurement was desired. Before the advent of highly
862 integrated microcontrollers and radios, WID research implemented custom

863 integrated circuit RF switch designs using a separate antenna than the main
864 telemetry antenna. Recent WIDs reported by Vilkomerson et al. (Vilkomer-
865 son et al., 2008), Cannata et al. (Cannata et al., 2012), and Rothfuss et
866 al. (Rothfuss et al., 2016) and Unadkat et al. (Unadkat et al., 2014, 2015)
867 and Gimbel et al. (Gimbel et al., 2014), use highly integrated radios and
868 radio/microcontroller systems on a chip which can achieve nanoampere cur-
869 rent draws in sleep mode, all while incorporating the switch using the same
870 antenna used for telemetry. For example, Rothfuss et al.’s reported WID
871 could only stay on for about 3 hours and 20 minutes continuously. However,
872 when using a sleep mode, their device achieved over three weeks of standby
873 time by waking up every 33 seconds to check for an incoming wake up signal
874 (Rothfuss et al., 2016).

875 *Diffraction Grating Transducers*

876 Previous WIDs reported that their piezoelectric transducer drive power
877 was in the tens of milliwatts or more (Gill and Meindl, 1975; Allen et al.,
878 1977; Cannata et al., 2012). With maximizing implant lifetime being such a
879 critical concern in WID research, it is interesting to note that little attention
880 is given to minimizing transducer power consumption. To date, the lowest
881 power required to drive a transducer for accurate direct-contact blood flow
882 monitoring is $500 \mu\text{W}$, reported by Vilkomerson for a double-beam diffraction
883 grating transducer (DGT) (Vilkomerson and Chilipka, 2004). Vilkomerson’s
884 research with DGTs has produced low power and angle-independent accurate
885 blood flow measurements (Vilkomerson et al., 1994, 1997, 1998; Vilkomerson,
886 2008).

887 **Outlook and Concluding Remarks**

888 Totally implantable wireless ultrasonic blood flow monitors are a useful
889 technology for providing accurate and chronic monitoring of blood flow, such
890 as in free flaps, artificial grafts, and freely behaving physiological studies.
891 This paper summarizes both early and recent WID advances that have lead
892 to more accurate, smaller, and longer lasting devices. While a desired accu-
893 racy can be tailored for the application, the size and implant lifetime of de-
894 vices throughout literature is insufficient to meet the demands for low foreign
895 body response and chronic monitoring, despite the continued advancement
896 of technology according to Moore’s law. The following provides a brief sum-
897 mary of findings and recommendations to achieve a desired accuracy, size,
898 and implant lifetime for the next generation of WIDs:

- 899 • Accurate WIDs have been in existence for many years. Little has
900 changed since the development of PW Doppler devices, which provide
901 superior accuracy over CW Doppler configurations. However, assessing
902 the application needs may preclude the need for a PW configuration.
903 The PW configuration is more complex and generally more power de-
904 manding than the CW configuration, which can lead to a size and
905 power savings for some applications, such as patency detection and ar-
906 eas of known flow and vascular dimensions. Another accuracy improve-
907 ment can be obtained by incorporating the recently developed DGT.
908 The DGT offers an angle-independent measurement, which eliminates
909 a major source of error – assumed insonation angle when determining
910 it is difficult or impractical. DGTs have been reported to consume very
911 little power for their accuracy.

912 • WID miniaturization and implant lifetime are strongly related (i.e.,
913 battery capacity or implanted antenna size). While COTS compo-
914 nents and PCBs are convenient for prototyping, reported WID devices
915 employing these remain bulky and offer limited room for increasing
916 implant lifetime. Integrated circuits have recently enabled ultra-small
917 and ultra-low power implantable medical devices that can operate with-
918 out batteries. Highly integrated WID devices have not been reported
919 in literature, and this technology stands to usher in the smallest and
920 least-power demanding devices.

921 • Implant lifetime needs to be maximized for chronic monitoring appli-
922 cations, such as wireless restenosis monitoring. Batteries are the most
923 common source of power for WIDs, but they are limited in available
924 power and/or recharge cycles. Incorporating energy scavenging tech-
925 nologies into WIDs can lead to batteryless devices with unlimited im-
926 plant lifetimes. However, some sources of power, such as thermoelectric
927 power or kinetic harvesting, do not offer a high enough energy density
928 for current WID designs. Both TWP and ultrasonic power transfer offer
929 solutions capable of delivering milliwatts of power safely to implants.

930 In TWP systems, the far-field and most importantly, near-field pow-
931 ering offer high energy densities that have successfully powered other
932 implanted devices in literature; however, their link range is often lim-
933 ited to a couple centimeters. Ultrasonic power delivery offers efficiency
934 improvements at greater implant depths and immunity to electromag-
935 netic interference; however, the piezoelectric transducers and front-end
936 electronics in WIDs used to sense Doppler blood flow signals will likely

937 suffer from interference by the large transmitted acoustic fields for pow-
938 ering. A workaround could be to charge an energy storage element (e.g.,
939 battery or supercapacitor) with ultrasonic power first, then power the
940 WID from the energy storage element with ultrasonic powering turned
941 off. A disadvantage to this technique is that continuous monitoring
942 would no longer be possible (i.e., for immediate detection of loss of
943 flow). To the best of the authors' knowledge, ultrasonic powering of
944 WIDs has yet to be investigated, and the use of ultrasonic powering of
945 WID stands to extend WIDs to implant depths unattainable by TWP
946 WIDs, which would be a valuable contribution to the field. For shal-
947 lower implant depths, WIDs should pursue TWP as a future source of
948 power to achieve chronic monitoring.

949 A barrier towards WID's adoption of TWP is that antenna size and link
950 efficiency need to be optimized for each specific application site, which
951 implies that no single TWP solution will be optimal for all implant
952 sites. However, for the case of a chronically implanted wireless resteno-
953 sis monitor, the stent itself serves as the antenna, obviating concerns
954 about implanting a bulky antenna. The large implanted stents used in
955 treating PAD stand to provide more power to an implant and should
956 be pursued first when using Doppler blood flow sensors for chronic
957 restenosis monitoring. Ultimately, for any chronic implant, whether
958 using ultrasonic powering or TWP, local heating of delicate tissues is
959 a concern and devices must adhere to regulatory limitations, which
960 impose power delivery maximums and increase the burden of efficient
961 electronic design.

962 Akin T, Najafi K, Bradley RM. A wireless implantable multichannel digital
963 neural recording system for a micromachined sieve electrode. *IEEE Journal*
964 *of Solid-State Circuits*, 1998;33:109–118.

965 Allen HV, Anderson MF, Meindl JD. Direct calibration of a totally im-
966 plantable pulsed Doppler ultrasonic blood flowmeter. *American Journal*
967 *of Physiology*, 1977;232:537–544.

968 Allen HV, Knutti JW, Meindl JD. Integrated circuits for a bidirectional
969 implantable pulsed Doppler ultrasonic blood flowmeter. *IEEE Journal of*
970 *Solid-State Circuits*, 1978;13:853–863.

971 Arger P, Iyooob S. *The Complete Guide to Vascular Ultrasound*. LWW med-
972 ical book collection. Lippincott Williams & Wilkins, 2004.
973 URL <https://books.google.com/books?id=L2WnFmR9oVwC>

974 Axelsson M, Dang Q, Pitsillides K, Munns S, Hicks J, Kassab GS. A novel,
975 fully implantable, multichannel biotelemetry system for measurement of
976 blood flow, pressure, ECG, and temperature. *Journal of Applied Physiol-*
977 *ogy*, 2007;102:1220–1228.

978 Baker DW. Pulsed ultrasonic Doppler blood-flow sensing. *IEEE Transactions*
979 *on Sonics and Ultrasonics*, 1970;17:170–184.

980 Baker RJ. *CMOS: circuit design, layout, and simulation*. Vol. 18. John Wiley
981 and Sons, Hoboken, New Jersey, 2011.

982 Bernardi P, Cavagnaro M, Pisa S, Piuzzi E. Specific absorption rate and tem-
983 perature increases in the head of a cellular-phone user. *IEEE transactions*
984 *on microwave theory and techniques*, 2000;48:1118–1126.

985 Boote EJ. Aapm/rsna physics tutorial for residents: Topics in us: Doppler
986 us techniques: Concepts of blood flow detection and flow dynamics 1.
987 Radiographics, 2003;23:1315–1327.

988 Brody WR, Meindl JD. Theoretical analysis of the CW Doppler ultrasonic
989 flowmeter. IEEE Transactions on Biomedical Engineering, 1974;BME-
990 21:183–192.

991 Brunner E. How ultrasound system considerations influence front-end com-
992 ponent choice. Analog Dialogue, 2002;36:1–4.

993 Burke MJ, Gleeson DT. A micropower dry-electrode ECG preamplifier. IEEE
994 Transactions on Biomedical Engineering, 2000;47:155–162.

995 Cannata JM, Chilipka T, Yang HC, Han S, Ham SW, Rowe VL, Weaver
996 FA, Shung KK, Vilkomerson D. Development of a flexible implantable
997 sensor for postoperative monitoring of blood flow. Journal of Ultrasound
998 in Medicine, 2012;31:1795–1802.

999 Cathignol D, Chapelon JY, Jossinet J, Lavandier B, Fourcade C. Detailed
1000 description of an implantable directional Doppler flowmeter. Biotelemetry,
1001 1975;3:117–128.

1002 Chandrakasan AP, Verma N, Daly DC. Ultralow-power electronics for
1003 biomedical applications. Annual Review of Biomedical Engineering,
1004 2008;10:247–274.

1005 Chen K, Mardini S, Chuang DC, Lin C, Cheng M, Lin Y, Huang W, Tsao C,
1006 Wei F. Timing of presentation of the first signs of vascular compromise dic-

1007 tates the salvage outcome of free flap transfers. *Plastic and Reconstructive*
1008 *Surgery*, 2007;120:187–195.

1009 Cho BC, Shin DP, Byun JS, Park JW, Baik BS. Monitoring flap for buried
1010 free tissue transfer: its importance and reliability. *Plastic and Reconstructive*
1011 *Surgery*, 2002;110:1249–1258.

1012 Chow EY, Chlebowski AL, Chakraborty S, Chappell WJ, Irazoqui PP.
1013 Fully wireless implantable cardiovascular pressure monitor integrated
1014 with a medical stent. *IEEE Transactions on Biomedical Engineering*,
1015 2010;57:1487–1496.

1016 Chow EY, Ouyang Y, Beier B, Chappell WJ, Irazoqui PP. Evaluation of car-
1017 diovascular stents as antennas for implantable wireless applications. *IEEE*
1018 *Transactions on Microwave Theory and Techniques*, 2009;57:2523–2532.

1019 Chowdary RP, Campbell SP, Rosenberg M, Hugo NE. Dermofluorometric
1020 prediction of flap survival. *Annals of plastic surgery*, 1987;19:154–157.

1021 Cleveland RF, Sylvar DM, Ulcek JL. Evaluating compliance with FCC guide-
1022 lines for human exposure to radiofrequency electromagnetic fields. Stan-
1023 dards Development Branch, Allocations and Standards Division, Office of
1024 Engineering and Technology, Federal Communications Commission, 1997.

1025 Cotté B, Lafon C, Dehollain C, Chapelon JY. Theoretical study for safe
1026 and efficient energy transfer to deeply implanted devices using ultrasound.
1027 *IEEE transactions on ultrasonics, ferroelectrics, and frequency control*,
1028 2012;59:1674–1685.

1029 Culjat MO, Goldenberg D, Tewari P, Singh RS. A review of tissue substitutes
1030 for ultrasound imaging. *Ultrasound in medicine & biology*, 2010;36:861–
1031 873.

1032 Dalecki D. Mechanical bioeffects of ultrasound. *Annual Review of Biomedical*
1033 *Engineering*, 2004;6:229–248.

1034 D’Ancona G, Karamanoukian H, Salerno T, Schmid S, Bergsland J. Flow
1035 measurement in coronary surgery. In: *The Heart Surgery Forum*. Vol. 2,
1036 1999. pp. 121–4.

1037 DeHennis AD, Wise KD. A fully integrated multisite pressure sensor for
1038 wireless arterial flow characterization. *Journal of Microelectromechanical*
1039 *Systems*, 2006;15:678–685.

1040 Denisov A, Yeatman E. Ultrasonic vs. inductive power delivery for miniature
1041 biomedical implants. In: *2010 International Conference on Body Sensor*
1042 *Networks*. IEEE, 2010. pp. 84–89.

1043 Di Pietro DM, Meindl JD. Optimal system design for an implantable CW
1044 Doppler ultrasonic flowmeter. *IEEE Transactions on Biomedical Engineer-*
1045 *ing*, 1978;25:255–264.

1046 DiPietro D, Meindl J. An implantable blood flowmeter using monolithic in-
1047 tegrated circuits. In: *1972 IEEE International Solid-State Circuits Confer-*
1048 *ence: Digest of Technical Papers*. Vol. 15. IEEE, 1972. pp. 184–185.

1049 DiPietro DM, Meindl JD. Integrated circuits for an implantable CW Doppler
1050 ultrasonic flowmeter. *IEEE Journal of Solid-State Circuits*, 1977;12:573–
1051 576.

- 1052 Disa JJ, Cordeiro PG, Hidalgo DA. Efficacy of conventional monitoring tech-
1053 niques in free tissue transfer: an 11-year experience in 750 consecutive
1054 cases. *Plastic and Reconstructive Surgery*, 1999;104:97–101.
- 1055 Fay L, Misra V, Sarpeshkar R. A micropower electrocardiogram amplifier.
1056 *IEEE Transactions on Biomedical Circuits and Systems*, 2009;3:312–320.
- 1057 Franklin DE, Watson NW, Pierson KE, Van Citters RL. Technique for radio
1058 telemetry of blood-flow velocity from unrestrained animals. *The American*
1059 *Journal of Medical Electronics*, 1965;5:24–28.
- 1060 Franklin DL. Blood velocity telemetered from untethered animals. *Nature*,
1061 1964;203:528–530.
- 1062 Franklin DL, Schlegel W, Rushmer RF. Blood flow measured by Doppler
1063 frequency shift of back-scattered ultrasound. *Science*, 1961;134:564–565.
- 1064 Frescura BL, Meindl JD. Micropower integrated circuits for an implantable
1065 bidirectional blood flowmeter. *IEEE Journal of Solid-State Circuits*,
1066 1976;11:817–825.
- 1067 Furnas H, Rosen JM. Monitoring in microvascular surgery. *Annals of plastic*
1068 *surgery*, 1991;26:265–272.
- 1069 Gabriel S, Lau R, Gabriel C. The dielectric properties of biological tissues: II.
1070 measurements in the frequency range 10 Hz to 20 GHz. *Physics in medicine*
1071 *and biology*, 1996;41:2251.
- 1072 Gill R, Meindl JD. Low power integrated circuits for an implantable pulsed

1073 Doppler ultrasonic blood flowmeter. *IEEE Journal of Solid-State Circuits*,
1074 1975;10:464–471.

1075 Gill RW. An implantable pulsed Doppler ultrasonic blood flowmeter using
1076 custom integrated circuits, 1975.

1077 Gill RW. Measurement of blood flow by ultrasound: accuracy and sources of
1078 error. *Ultrasound in Medicine and Biology*, 1985;11:625–641.

1079 Gill RW, Hottinger CF, Meindl JD. Doppler instrumentation for measuring
1080 blood velocity and flow. In: *Cardiovascular Imaging and Image Processing:
1081 Theory and Practice*. International Society for Optics and Photonics, 1976.
1082 pp. 53–64.

1083 Gill RW, Meindl JD. Optimal system design of the pulsed Doppler ultrasonic
1084 blood flowmeter. In: *1973 Ultrasonics Symposium*, 1973. pp. 88–93.

1085 Gill RW, Meindl JD, Haase WC. An implantable pulsed Doppler ultrasonic
1086 flowmeter. In: *24th Proceedings of the annual Conference on Engineering
1087 in Medicine and Biology*. Vol. 13, 1971. p. 268.

1088 Gimbel ML, Rothfuss MA, Unadkat JV, Mickle MH, Sejdic E. Venous flow
1089 monitoring using an entirely implanted, wireless Doppler sensor. *Plastic
1090 and Reconstructive Surgery*, 2014;133:126.

1091 Goodstein WA, Buncke Jr HJ. Patterns of vascular anastomoses vs. success
1092 of free groin flap transfers. *Plastic and Reconstructive Surgery*, 1979;64:37–
1093 40.

- 1094 Graham BH, Walton RL, Elings VB, Lewis FR. Surface quantification of in-
1095 jected fluorescein as a predictor of flap viability. *Plastic and reconstructive*
1096 *surgery*, 1983;71:826–831.
- 1097 Gräns A, Axelsson M, Pitsillides K, Olsson C, Höjesjö J, Kaufman RC,
1098 Cech Jr J. A fully implantable multi-channel biotelemetry system for mea-
1099 surement of blood flow and temperature: a first evaluation in the green
1100 sturgeon. *Hydrobiologia*, 2009;619:11–25.
- 1101 Guillemaud JP, Seikaly H, Cote D, Allen H, Harris JR. The implantable cook-
1102 swartz Doppler probe for postoperative monitoring in head and neck free
1103 flap reconstruction. *Archives of Otolaryngology–Head and Neck Surgery*,
1104 2008;134:729–734.
- 1105 Guo Z, Durand LG, Allard L, Cloutier G, Lee HC. Classification of lower
1106 limb arterial stenoses from doppler blood flow signal analysis with time-
1107 frequency representation and pattern recognition techniques. *Ultrasound*
1108 *in medicine & biology*, 1994;20:335–346.
- 1109 Gupta M. An economic analysis of implantable Doppler technology in head
1110 and neck reconstruction. Ph.D. thesis, Université d’Ottawa/University of
1111 Ottawa, 2012.
- 1112 Hartley CJ, Cole JS. An ultrasonic pulsed Doppler system for measuring
1113 blood flow in small vessels. *Journal of Applied Physiology*, 1974;37:626–
1114 629.
- 1115 Hong JP, Yim JH, Malzone G, Lee KJ, Dashti T, Suh HS. The thin gluteal

1116 artery perforator free flap to resurface the posterior aspect of the leg and
1117 foot. *Plastic and Reconstructive Surgery*, 2014;133:1184–1191.

1118 Hoskins PR. Physical properties of tissues relevant to arterial ultrasound
1119 imaging and blood velocity measurement. *Ultrasound in Medicine and Bi-*
1120 *ology*, 2007;33:1527–1539.

1121 Jow UM, Ghovanloo M. Design and optimization of printed spiral coils for
1122 efficient transcutaneous inductive power transmission. *IEEE Transactions*
1123 *on Biomedical Circuits and Systems*, 2007;1:193–202.

1124 Kang MJ, Chung CH, Chang YJ, Kim KH. Reconstruction of the lower
1125 extremity using free flaps. *Archives of Plastic Surgery*, 2013;40:575–583.

1126 Keikhosravy K, Kamalinejad P, Keikhosravy L, Zargaran-Yazd A, Takahata
1127 K, Mirabbasi S. A fully integrated telemonitoring system for diagnosing
1128 in-stent restenosis. In: 2014 IEEE Biomedical Circuits and Systems Con-
1129 ference. IEEE, 2014. pp. 392–395.

1130 Keikhosravy K, Zargaran-Yazd A, Mirabbasi S. On the use of smart stents for
1131 monitoring in-stent restenosis. In: 2012 Annual International Conference
1132 of the IEEE Engineering in Medicine and Biology Society. IEEE, 2012. pp.
1133 3231–3234.

1134 Kempton SJ, Poore SO, Chen JT, Afifi AM. Free flap monitoring using an
1135 implantable anastomotic venous flow coupler: Analysis of 119 consecu-
1136 tive abdominal-based free flaps for breast reconstruction. *Microsurgery*,
1137 2015;35:337–344.

- 1138 Kiani M, Jow UM, Ghovanloo M. Design and optimization of a 3-coil induc-
1139 tive link for efficient wireless power transmission. *Biomedical Circuits and*
1140 *Systems, IEEE Transactions on*, 2011;5:579–591.
- 1141 Kiourti A, Christopoulou M, Nikita KS. Performance of a novel minia-
1142 ture antenna implanted in the human head for wireless biotelemetry. In:
1143 2011 IEEE International Symposium on Antennas and Propagation. IEEE,
1144 2011. pp. 392–395.
- 1145 Kong W, Rollins DL, Ideker RE, Smith WM. Design and initial evaluation of
1146 an implantable sonomicrometer and CW Doppler flowmeter for simultane-
1147 ous recordings with a multichannel telemetry system. *IEEE Transactions*
1148 *on Biomedical Engineering*, 2005;52:1365–1367.
- 1149 Liu W, Vichienchom K, Clements M, DeMarco SC, Hughes C, McGucken E,
1150 Humayun MS, De Juan E, Weiland JD, Greenberg R. A neuro-stimulus
1151 chip with telemetry unit for retinal prosthetic device. *IEEE Journal of*
1152 *Solid-State Circuits*, 2000;35:1487–1497.
- 1153 Liu Y, Zhao Y, Huang J, Wu Y, Jiang L, Wang G, Li W, Chen X, Shi R.
1154 Analysis of 13 cases of venous compromise in 178 radial forearm free flaps
1155 for intraoral reconstruction. *International Journal of Oral and Maxillofacial*
1156 *Surgery*, 2012;41:448–452.
- 1157 Lohman RF, Langevin CJ, Bozkurt M, Kundu N, Djohan R. A prospective
1158 analysis of free flap monitoring techniques: physical examination, external
1159 Doppler, implantable Doppler, and tissue oximetry. *Journal of Reconstructive*
1160 *Microsurgery*, 2013;29:051–056.

- 1161 Mazzilli F, Lafon C, Dehollain C. A 10.5 cm ultrasound link for deep im-
1162 planted medical devices. *IEEE transactions on biomedical circuits and*
1163 *systems*, 2014;8:738–750.
- 1164 Mazzilli F, Peisino M, Mitouassiyou R, Cotté B, Thoppay P, Lafon C,
1165 Favre P, Meurville E, Dehollain C. *In-vitro* platform to study ultrasound
1166 as source for wireless energy transfer and communication for implanted
1167 medical devices. In: 2010 Annual International Conference of the IEEE
1168 Engineering in Medicine and Biology. IEEE, 2010. pp. 3751–3754.
- 1169 McDermott MM, Guralnik JM, Ferrucci L, Tian L, Liu K, Liao Y, Green
1170 D, Sufit R, Hoff F, Nishida T, et al. Asymptomatic peripheral arterial
1171 disease is associated with more adverse lower extremity characteristics than
1172 intermittent claudication. *Circulation*, 2008;117:2484–2491.
- 1173 McLeod FD, Anliker M. Multiple gate pulsed Doppler flowmeter. In: *IEEE*
1174 *Transactions on sonics and ultrasonics*. No. 3, 1971. p. 401.
- 1175 Meindl J. Implantable ultrasonic blood flowmeters. In: *International Teleme-*
1176 *tering Conference Proceedings*. International Foundation for Telemetry,
1177 1972.
- 1178 Meindl JD, McVittie JP, DiPietro DM. An implantable ultrasonic blood
1179 flowmeter utilizing monolithic integrated circuits. In: *Proceedings of the*
1180 *8th International Conference on Engineering in Medical and Biological*
1181 *Engineering and the 22nd Annual Conference EMB*. Chicago, Illinois, 1969.
- 1182 Morais JM, Papadimitrakopoulos F, Burgess DJ. Biomaterials/tissue inter-

1183 actions: possible solutions to overcome foreign body response. The AAPS
1184 Journal, 2010;12:188–196.

1185 Muradin GSR, Bosch JL, Stijnen T, Hunink MGM. Balloon dilation and
1186 stent implantation for treatment of femoropopliteal arterial disease: Meta-
1187 analysis. Radiology, 2001;221:137–145.

1188 Neihart NM, Harrison RR. Micropower circuits for bidirectional wireless
1189 telemetry in neural recording applications. IEEE Transactions on Biomed-
1190 ical Engineering, 2005;52:1950–1959.

1191 Nelson TR, Pretor DH. The Doppler signal: where does it come from and
1192 what does it mean? American Journal of Roentgenology, 1988;151:439–
1193 447.

1194 O’Brien B, Morrison WA, Ishida H, MacLeod AM, Gilbert A. Free flap trans-
1195 fers with microvascular anastomoses. British Journal of Plastic Surgery,
1196 1974;27:220–230.

1197 Occhiuzzi C, Contri G, Marrocco G. RFID STENTag for passive vascular
1198 monitoring. In: Proceedings of the 5th European Conference on Antennas
1199 and Propagation. IEEE, 2011. pp. 3476–3478.

1200 Occhiuzzi C, Contri G, Marrocco G. Design of implanted RFID tags for
1201 passive sensing of human body: the STENTag. IEEE Transactions on
1202 Antennas and Propagation, 2012;60:3146–3154.

1203 Oliver DW, Whitaker IS, Giele H, Critchley P, Cassell O. The cook–swartz
1204 venous Doppler probe for the post-operative monitoring of free tissue trans-

- 1205 fers in the United Kingdom: a preliminary report. *British Journal of Plastic*
1206 *Surgery*, 2005;58:366–370.
- 1207 Olivo J, Carrara S, De Micheli G. Energy harvesting and remote powering
1208 for implantable biosensors. *IEEE Sensors Journal*, 2011;11:1573–1586.
- 1209 Paydar KZ, Hansen SL, Chang DS, Hoffman WY, Leon P. Implantable
1210 venous Doppler monitoring in head and neck free flap reconstruc-
1211 tion increases the salvage rate. *Plastic and Reconstructive Surgery*,
1212 2010;125:1129–1134.
- 1213 Peronneau PA, Leger F. Doppler ultrasonic pulsed blood flowmeter. In: *Proc.*
1214 *8th Int. Conf. Med. Biol. Eng*, 1969. pp. 10–11.
- 1215 Poon AS, O’Driscoll S, Meng TH. Optimal operating frequency in wireless
1216 power transmission for implantable devices. In: *29th Annual International*
1217 *Conference of the IEEE Engineering in Medicine and Biology Society.*
1218 IEEE, 2007. pp. 5673–5678.
- 1219 Poon AS, O’Driscoll S, Meng TH. Optimal frequency for wireless power trans-
1220 mission into dispersive tissue. *IEEE Transactions on Antennas and Prop-*
1221 *agation*, 2010;58:1739–1750.
- 1222 Pryor SG, Moore EJ, Kasperbauer JL. Implantable Doppler flow system: Ex-
1223 perience with 24 microvascular free-flap operations. *Otolaryngology-Head*
1224 *and Neck Surgery*, 2006;135:714–718.
- 1225 Rabaey JM, Mark M, Chen D, Sutardja C, Tang C, Gowda S, Wagner M,
1226 Werthimer D. Powering and communicating with mm-size implants. In:

1227 2011 Design, Automation and Test in Europe Conference and Exhibition,
1228 2011. pp. 1–6.

1229 Radermacher J, Chavan A, Bleck J, Vitzthum A, Stoess B, Gebel MJ, Galan-
1230 ski M, Koch KM, Haller H. Use of Doppler ultrasonography to predict
1231 the outcome of therapy for renal-artery stenosis. *New England Journal of*
1232 *Medicine*, 2001;344:410–417.

1233 Radziemski L, Makin IRS. In vivo demonstration of ultrasound power de-
1234 livery to charge implanted medical devices via acute and survival porcine
1235 studies. *Ultrasonics*, 2016;64:1–9.

1236 Razavi B. Challenges in portable rf transceiver design. *IEEE Circuits and*
1237 *Devices Magazine*, 1996;12:12–25.

1238 Roe D. Secrets of Micra: How medtronic reinvented the pacemaker. [http:](http://www.meddeviceonline.com/doc/secrets-of-micra-0001)
1239 [//www.meddeviceonline.com/doc/secrets-of-micra-0001](http://www.meddeviceonline.com/doc/secrets-of-micra-0001), Online; accessed
1240 2016-09-25.

1241 Rosenberg JJ, Fornage BD, Chevray PM. Monitoring buried free flaps: limi-
1242 tations of the implantable Doppler and use of color duplex sonography as a
1243 confirmatory test. *Plastic and Reconstructive Surgery*, 2006;118:109–113.

1244 Rothfuss MA, Franconi NG, Unadkat JV, Gimbel ML, Star A, Mickle MH,
1245 Sejdíć E. A system for simple real-time anastomotic failure detection and
1246 wireless blood flow monitoring in the lower limbs. *IEEE Journal of Trans-*
1247 *lational Engineering in Health and Medicine*, 2016. Accepted.

1248 Rozen WM, Ang GG, McDonald AH, Sivarajah G, Rahdon R, Acosta R,
1249 Thomas DJ. Sutured attachment of the implantable Doppler probe cuff for

1250 large or complex pedicles in free tissue transfer. *Journal of Reconstructive*
1251 *Microsurgery*, 2011;27:99–102.

1252 Sarpeshkar R. *Ultra low power bioelectronics: fundamentals, biomedical ap-*
1253 *plications, and bio-inspired systems*. Cambridge University Press, 2010.

1254 Sarpeshkar R, Salthouse C, Sit JJ, Baker MW, Zhak SM, Lu TT, Turicchia L,
1255 Balster S. An ultra-low-power programmable analog bionic ear processor.
1256 *IEEE Transactions on Biomedical Engineering*, 2005;52:711–727.

1257 Sauer C, Stanacevic M, Cauwenberghs G, Thakor N. Power harvesting and
1258 telemetry in cmos for implanted devices. *IEEE Transactions on Circuits*
1259 *and Systems I: Regular Papers*, 2005;52:2605–2613.

1260 Schrey AR, Kinnunen IA, Grénman RA, Minn HR, Aitasalo KM. Monitor-
1261 ing microvascular free flaps with tissue oxygen measurement and PET.
1262 *European Archives of Oto-Rhino-Laryngology*, 2008;265:105–113.

1263 Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial
1264 disease in the United States results from the national health and nutrition
1265 examination survey, 1999–2000. *Circulation*, 2004;110:738–743.

1266 Service IR. Yearly average currency exchange rates translating foreign cur-
1267 rency into U.S. dollars. [https://www.irs.gov/individuals/international-](https://www.irs.gov/individuals/international-taxpayers/yearly-average-currency-exchange-rates)
1268 [taxpayers/yearly-average-currency-exchange-rates](https://www.irs.gov/individuals/international-taxpayers/yearly-average-currency-exchange-rates), 2016. [Online; ac-
1269 cessed 06-June-2016].

1270 Shung KK. *Diagnostic ultrasound: Imaging and blood flow measurements*.
1271 CRC press, Boca Raton, FL, 2005.

- 1272 Si P, Hu AP, Malpas S, Budgett D. A frequency control method for regulating
1273 wireless power to implantable devices. *IEEE Transactions on Biomedical*
1274 *Circuits and Systems*, 2008;2:22–29.
- 1275 Smit JM, Zeebregts CJ, Acosta R, Werker PM. Advancements in free flap
1276 monitoring in the last decade: a critical review. *Plastic and reconstructive*
1277 *surgery*, 2010;125:177–185.
- 1278 Swartz WM, Jones NF, Cherup L, Klein A. Direct monitoring of microvascu-
1279 lar anastomoses with the 20-mhz ultrasonic Doppler probe: An experimen-
1280 tal and clinical study. *Plastic and Reconstructive Surgery*, 1988;81:149–158.
- 1281 Takahata K, DeHennis A, Wise KD, Gianchandani YB. Stentenna: a micro-
1282 machined antenna stent for wireless monitoring of implantable microsensors.
1283 In: *Proceedings of the 25th Annual International Conference of the*
1284 *IEEE Engineering in Medicine and Biology Society*. Vol. 4. IEEE, 2003.
1285 pp. 3360–3363.
- 1286 Takahata K, Gianchandani YB, Wise KD. Micromachined antenna stents
1287 and cuffs for monitoring intraluminal pressure and flow. *Journal of Micro-*
1288 *electromechanical Systems*, 2006;15:1289–1298.
- 1289 Tang SC, Jolesz FA, Clement GT. A wireless batteryless deep-seated
1290 implantable ultrasonic pulser-receiver powered by magnetic coupling.
1291 *IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control*,
1292 2011;58:1211–1221.
- 1293 Tang SC, Vilkomerson D, Chilipka T. Magnetically-powered implantable

- 1294 Doppler blood flow meter. In: 2014 IEEE International Ultrasonics Sym-
1295 posium (IUS). IEEE, 2014. pp. 1622–1625.
- 1296 Unadkat J, Rothfuss M, Mickle MH, Sejdic E, Gimbel M. Entirely implanted
1297 wireless Doppler sensor for monitoring venous flow. *Plastic and Recon-*
1298 *structive surgery*, 2014;134:57–58.
- 1299 Unadkat JV, Rothfuss M, Mickle MH, Sejdic E, Gimbel ML. The develop-
1300 ment of a wireless implantable blood flow monitor. *Plastic and reconstruc-*
1301 *tive surgery*, 2015;136:199–203.
- 1302 Upile T, Jerjes W, El Maaytah M, Hopper C, Searle A, Wright A. Direct
1303 microvascular monitoring of a free autologous jejunal flap using microen-
1304 doscopy: a case report. *BMC Ear, Nose and Throat Disorders*, 2006;6:14–
1305 19.
- 1306 Van Der Togt R, van Lieshout EJ, Hensbroek R, Beinat E, Binnekade J,
1307 Bakker P. Electromagnetic interference from radio frequency identification
1308 inducing potentially hazardous incidents in critical care medical equip-
1309 ment. *Journal of the American Medical Association*, 2008;299:2884–2890.
- 1310 Verma N, Shoeb A, Bohorquez J, Dawson J, Guttag J, Chandrakasan AP. A
1311 micro-power EEG acquisition soc with integrated feature extraction pro-
1312 cessor for a chronic seizure detection system. *IEEE Journal of Solid-State*
1313 *Circuits*, 2010;45:804–816.
- 1314 Vilkomerson D. Double-beam diffraction-grating transducers for improved
1315 blood flow measurement. In: 2008 IEEE Ultrasonics Symposium, 2008.
1316 pp. 1064–1067.

- 1317 Vilkomerson D, Chilipka T. Implantable doppler system for self-monitoring
1318 vascular grafts. In: 2004 IEEE Ultrasonics Symposium. Vol. 1, 2004. pp.
1319 461–465 Vol.1.
- 1320 Vilkomerson D, Chilipka T, Bogan J, Blebea J, Choudry R, Wang J, Salva-
1321 tore M, Rotella V, Soundararajan K. Implantable ultrasound devices. In:
1322 Medical Imaging. International Society for Optics and Photonics, 2008.
1323 pp. 69200C–69200C.
- 1324 Vilkomerson D, Lyons D, Chilipka T. Diffractive transducers for angle-
1325 independent velocity measurements. In: Proc. of the 1994 IEEE Ultra-
1326 sonics Symposium, 1994. Vol. 3, 1994. pp. 1677–1682.
- 1327 Vilkomerson D, Lyons D, Chilipka T, Delamere M, Lopath P, Palanchon
1328 P, Shung K. Clinical blood flow measurements using diffraction-grating
1329 transducers. In: Proc. of the 1998 IEEE Ultrasonics Symposium. Vol. 2,
1330 1998. pp. 1501–1508.
- 1331 Vilkomerson D, Lyons D, Chilipka T, Lopath P, Shung KK. Diffraction-
1332 grating transducers. In: Proc. of the 1997 IEEE Ultrasonics Symposium.
1333 Vol. 2, 1997. pp. 1691–1696.
- 1334 Webster JG. Measurement of flow and volume of blood. Medical instrumen-
1335 tation: application and design, 1998;2.
- 1336 Wells PNT. A range-gated ultrasonic Doppler system. Medical and Biological
1337 Engineering, 1969;7:641–652.
- 1338 Wilson J, Ismail M. Rf design for first-pass silicon success. In: Radio Design
1339 in Nanometer Technologies. Springer, 2006. pp. 287–314.

- 1340 Wu C, Lin P, Chew K, Kuo Y. Free tissue transfers in head and neck recon-
1341 struction: complications, outcomes and strategies for management of flap
1342 failure: analysis of 2019 flaps in single institute. *Microsurgery*, 2013;34:339–
1343 344.
- 1344 Yonezawa Y, Caldwell WM, Schadt JC, Hahn AW. A miniaturized ultra-
1345 sonic flowmeter and telemetry transmitter for chronic animal blood flow
1346 measurements. *Biomedical Sciences Instrumentation*, 1989;25:107.
- 1347 Yonezawa Y, Nakayama T, Ninomiya I, Caldwell WM. Radio telemetry di-
1348 rectional ultrasonic blood flowmeter for use with unrestrained animals.
1349 *Medical and Biological Engineering and Computing*, 1992;30:659–665.
- 1350 Yu P, Chang DW, Miller MJ, Reece G, Robb GL. Analysis of 49 cases of flap
1351 compromise in 1310 free flaps for head and neck reconstruction. *Head and*
1352 *Neck*, 2009;31:45–51.
- 1353 Zargham M, Gulak PG. Maximum achievable efficiency in near-field coupled
1354 power-transfer systems. *IEEE Transactions on Biomedical Circuits and*
1355 *Systems*, 2012;6:228–245.
- 1356 Zhang F, Liu X, Hackworth SA, Scلابassi RJ, Sun M. *In vitro* and *in vivo*
1357 studies on wireless powering of medical sensors and implantable devices.
1358 In: *Life Science Systems and Applications Workshop*. IEEE, 2009. pp.
1359 84–87.
- 1360 Zhang T, Dyalram-Silverberg D, Bui T, Caccamese J, Lubek J. Analysis of
1361 an implantable venous anastomotic flow coupler: experience in head and

1362 neck free flap reconstruction. International journal of oral and maxillofacial
1363 surgery, 2012;41:751–755.

1364 Zhou W, He M, Liao Y, Yao Z. Reconstructing a complex central facial
1365 defect with a multiple-folding radial forearm flap. Journal of Oral and
1366 Maxillofacial Surgery: Official Journal of the American Association of Oral
1367 and Maxillofacial Surgeons, 2014;72:836–e1.

1368 **Figure Captions**

1369 **Figure 1:** System-level block diagram of the nondirectional Pulsed Wave
1370 Doppler flowmeter. Adapted from (Shung, 2005; Boote, 2003; Brunner,
1371 2002).

1372 **Figure 2:** System-level block diagram of the nondirectional Continuous Wave
1373 Doppler flowmeter.

1374 **Tables**

1375 **Table 1:** Summary of blood flow monitoring modalities and their clinical
 1376 advantages and disadvantages.

1377

1378

Modality	Advantages	Disadvantages
Color Duplex Ultrasound (Smit et al., 2010)	non-invasive, applies to all sites, direct monitoring	Expensive, experienced personnel.
Fluorescein (Swartz et al., 1988; Graham et al., 1983; Furnas and Rosen, 1991; Chowdary et al., 1987)	inexperienced personnel, rapid	unreliable, indirect monitoring, only cutaneous flaps and replants, undesirable side effects to fluorescein
Laser Doppler Flowmetry (Swartz et al., 1988; Smit et al., 2010)	low cost, continuous, non-invasive	limited penetration depth, slightly experienced personnel
Microdialysis (Smit et al., 2010)	applies to all sites	expensive, invasive, experienced personnel, indirect monitoring
Microendoscopy (Upile et al., 2006)	direct monitoring	expensive, cumbersome
Near-Infrared Spectroscopy (Smit et al., 2010; Lohman et al., 2013)	inexperienced personnel, non-invasive	moderately expensive, slow response, limited penetration depth, interference from ambient light
Photoplethysmography (Swartz et al., 1988; Furnas and Rosen, 1991)	non-invasive	no quantitative information, only cutaneous flaps, unreliable for dark skin
Positron Emission Tomography (Schrey et al., 2008)	direct monitoring, includes buried flaps	cumbersome, expensive
Thermocouple (Swartz et al., 1988; Furnas and Rosen, 1991)	continuous	no quantitative information, indirect monitoring, can't monitor muscle perfusion
Transcutaneous P_{O_2} (Swartz et al., 1988; Schrey et al., 2008)	inexperienced personnel	no quantitative information, indirect monitoring, invasive
Wired Implantable Doppler (Smit et al., 2010)	low cost, inexperienced personnel, applies to all sites, direct monitoring	invasive, prone to unreliability, foreign material
Wireless Implantable Doppler (Smit et al., 2010)	inexperienced personnel, applies to all sites, direct monitoring	invasive, size, foreign material

1379 **Table 2:** Summary of Reported WID device accuracy.

1380

1381

Con-fig.	Year & Reference	Accuracy	Technical Notes
CW	1978 (Di Pietro and Meindl, 1978)	$\pm 20\%$ from theory	any vessel size and any flow profile; mean Doppler shift by ZCC
	1992 (Yonezawa et al., 1992)	linearity was within $\pm 1\%$ to the actual average flow velocity over measured range	directional; 20 cm/s – 150 cm/s tested flow rate range
	2004 (Vilkomerson and Chilipka, 2004), 2008 (Vilkomerson et al., 2008)	average blood flow velocity accuracy error less than 5%	directional; using diffraction grating transducers (DGT)
	2012 (Cannata et al., 2012)	average blood flow velocity accuracy errors less than 6%; peak blood flow velocity measurement deviating only 1.7% from measurements performed with a duplex ultrasound system	directional; using diffraction grating transducers (DGT)
	2014 (Tang et al., 2014)	< 6% deviation	directional; one measurement; reported 22.6 cm/s compared to true 24 cm/s flow
	2014, 2015 (Gimbel et al., 2014; Unadkat et al., 2014, 2015), 2016 (Rothfuss et al., 2016)	< $\pm 5\%$ above 8.00 mL/min; between -0.8% and +1.2% at largest calibrated flow rate	nondirectional; binary flow/no-flow scenarios measured
PW	1974 (Hartley and Cole, 1974)	reported as accurate up to 100 ml/min flows	directional; transcutaneously excited probe (i.e., no implanted electronics)
	1975 (Gill and Meindl, 1975)	$\pm 15\%$ blood flow volume estimation	nondirectional
	1977 (Allen et al., 1977)	$+2.0 \pm 8.7\%$	nondirectional; 77 trials

1382 **Table 3:** Summary of Reported WIDs with reported Implant Size and Minia-
 1383 turization Technique.

Year & Reference	Reported Implant Size	Miniaturization Technique
1974 (Hartley and Cole, 1974)	3 cm diameter coil (only reported coil size)	inductively coupled to transducer (all electronics external)
1975 (Gill and Meindl, 1975)	60 cm^3 , 20% by electronics	Custom Integrated Circuits; further demodulation and processing externally
1975 (Cathignol et al., 1975)	4 x 4 cm (only reported antenna size)	performing demodulation, filtering, processing externally
1978 (Allen et al., 1978)	3.8 x 2.8 x 0.8 cm implanted package	Custom Integrated Circuits; further demodulation and processing externally
1978 (Di Pietro and Meindl, 1978)	< 36 cm^3 ; 6.1 x 4.1 x 1.3 cm (encapsulated electronics, battery, and antennas dimensions)	Custom Integrated Circuits
1989 (Yonezawa et al., 1989)	12.4 cm^3 ; 25 mm x 33 mm PCB	COTS parts; performing demodulation, filtering, processing externally
1992 (Yonezawa et al., 1992)	27 cm^3	COTS parts; performing demodulation, filtering, processing externally
2008 (Vilkomerson et al., 2008)	PCB ₁ : ~3.5 x 5.5 cm; PCB ₂ : ~2.5 x 4.9 cm	COTS parts; two PCBs; stacked; SMT
2012 (Cannata et al., 2012)	one board from (Vilkomerson et al., 2008)	COTS parts; SMT
2014 (Tang et al., 2014)	7 cm^2 (total PCB area)	COTS parts; two PCBs; SMT; performing demodulation, filtering, processing externally; small battery wirelessly recharged
2014, 2015, 2016 (Rothfuss et al., 2016; Gimbel et al., 2014; Unadkat et al., 2014, 2015)	1.7 cm^3 (electronics and antenna only); 18.04 cm^3 (encapsulated electronics, battery, and antennas)	COTS parts; 4-layer two-sided PCB; SMT




Figure 1: System-level block diagram of the nondirectional Pulsed Wave Doppler flowmeter. Adapted from (Shung, 2005; Boote, 2003; Brunner, 2002).




Figure 2: System-level block diagram of the nondirectional Continuous Wave Doppler flowmeter.